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ABSTRACT 
The Role of Interstitial Fluid Flow on Breast Cancer Progression 
Alimatou M. Tchafa 
Supervisor: Adrian Shieh, Ph.D. 
 
 
The majority of deaths associated with breast cancer result from the ability of 
the cancer cells to invade the surrounding environment and spread to distant sites. 
The tumor microenvironment includes a variety of biophysical forces whose effects 
are known to influence cancer invasion and progression. Interstitial fluid flow (IFF) is 
one such force that is present in normal breast tissue and elevated in tumors. The 
focus of this dissertation was to study the effects of IFF coupled with overexpression 
of the proto-oncogene HER2 on breast cancer progression. The combined roles IFF 
and HER2 play on invasion had never been studied, especially in the context of how 
they may together influence the transition from ductal carcinoma in situ (DCIS) to 
invasive ductal carcinoma (IDC).  
Using 3-dimensional cell culture-based assays, we demonstrated that IFF 
activates molecular mechanisms that are HER2-independent and leads to invasion of 
different stages of tumor development through the phosphoinositide-3-kinase (PI3K). 
This phenomenon was observed both in single cells and in breast cancer-like acini 
structures. We identified that in normal cells, IFF-induced PI3K activation was 
modulated by EGFR, a growth factor whose signaling is tightly controlled in normal 
tissue. In invasive cancer cells, IFF-induced PI3K activation was modulated by the 
metastasis-associated chemokine receptor CXCR4. Furthermore, we observed that 
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IFF-induced CXCR4 signaling only occurred in cells that have undergone EMT. 
Finally, using an approach to isolate IFF responsive cells, we observed that HER2 
positive epithelial cells that invaded in response to IFF developed mesenchymal-like 
characteristics and displayed a lower sensitivity to HER2 drug treatment. Taken 
together, our findings suggest for the first time the role IFF plays on cellular 
transformation and drug resistance. In addition, they reveal IFF as a major contributor 
to breast cancer progression and highlight its implications on breast cancer therapy. 
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INTRODUCTION 
The majority of deaths associated with cancer result from cancer cell invasion 
and metastasis. The causes of cancer invasion have been the focus of many research 
studies but much remains unknown. Although the expression of ErbB2 in pre-
invasive cells is a risk factor for invasion and cancer progression, not all cells 
expressing this proto-oncogene develop invasive phenotypes. It has become 
increasingly apparent that cancer progression does not solely depend on the functions 
of cancer cells. There exist a crosstalk between cancer cells, other cells of the tumor 
microenvironment, and physical properties of the neoplastic tissue and each 
participate in the acquired capability of invasive growth and metastasis. Change in 
interstitial fluid flow (IFF) is one example of altered biomechanical characteristics of 
tumor tissue that has been linked to cancer invasion. IFF is elevated in solid tumors 
and can modulate stromal and tumor cell invasion. The focus of this dissertation was 
to study the effects of IFF on breast cancer progression. The combined role IFF and 
ErbB2 expression play on invasion had never been studied, especially in the context 
of how together they may influence the transition from ductal carcinoma in situ 
(DCIS) to invasive ductal carcinoma (IDC).  
We initially hypothesized that IFF activates ErbB2 pathways leading to 
invasion of non-invasive ErbB2 expressing DCIS cells. However this hypothesis was 
quickly proven wrong and we demonstrated instead that although IFF is ErbB2-
independent, it leads to invasion of different stages of tumor development through the 
PI3K molecular pathway and epithelial-to-mesenchymal transition (EMT). 
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This dissertation is organized into 6 main chapters. In the first chapter, I give a 
thorough review of the current scientific knowledge on breast cancer invasion, IFF 
and EMT. Then, I present my findings and observations in the next four chapters 
organized into four independent papers. In chapter II, I highlight and support the 
observation that increased invasion due to IFF in breast cancer is independent of 
ErbB2 expression. Relying primarily on our 3D invasion assay, I used both invasive 
and non-invasive breast cancer cell lines overexpressing ErbB2. Pharmacological 
inhibitors against various members of the ErbB2 pathway were also used to test the 
importance of these proteins on flow specific invasion.   
In chapter III, I present evidence that IFF induces EMT in pre-invasive cells. 
The objective of this chapter was to identify the potential role of IFF in EMT and the 
hypothesis was that IFF is able to increase invasion of cells by inducing the loss of 
epithelial markers and increasing the expression of mesenchymal characteristics in 
cells. There were 2 separate approaches used in this chapter in order to prove the 
hypothesis. The first method compared changes in gene and protein expression of 
EMT markers between cells after short exposure to IFF (24 hours). The second 
method used an approach to isolate flow responsive cells after multiple exposures to 
IFF and compared their protein profiles to cells not exposed to IFF. Both methods 
demonstrated that epithelial cells invading in response to IFF had decreased 
expression of epithelial characteristics. In addition, these flow responsive cells 
displayed a lower sensitivity to HER2 drug treatments.  
The focus of chapter IV is on elucidating the signaling pathways activated by 
IFF in HER2 positive cells. By measuring the changes in protein expression and 
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phosphorylation of various cell membrane receptors in both pre-invasive and invasive 
cells after IFF exposure, I demonstrate that IFF induces invasion of breast cancer cells 
via activation of phosphoinositide-3-kinase (PI3K). Using both post-EMT and pre-
EMT cells, I then show evidence that IFF-induced invasion and PI3K activation is 
modulated by CXCR4 only in cells that have undergone EMT. Furthermore, I 
conclude that EMT alters the response of cells to IFF with data showing that once 
pre-EMT cells are induced to undergo EMT through growth factor treatment, their 
response to IFF switch from CXCR4-independent to CXCR4-dependent.  
In chapter V, I focus on the role IFF plays in initiation of invasion in breast 
cancer multicellular structures or acini. Here I first developed a 3-dimensional breast 
tissue model mimicking normal, DCIS-like, and IDC-like spheroid structures under 
IFF. The hypothesis of this chapter is that IFF alone is able to induce invasion 
initiation of DCIS-like structures. The data presented in this chapter using this model, 
supports our hypothesis. It was observed that IFF decreased levels of basement 
membrane proteins (laminin V and collagen IV), increased PI3K phosphorylation, 
and increased protrusions in pre-invasive spheroids.  
The final chapter of this dissertation (chapter VI) highlights the main findings 
of the project and presents the scientific impacts of the research. Identifying the 
mechanisms involved in this flow specific invasion has enhanced our current 
knowledge of the role IFF plays on the breast tumor microenvironment. It may also 
serve as a basis for therapeutic development for the treatment of DCIS patients.  
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CHAPTER 1: BACKGROUND 
1.1 Introduction to Breast Cancer 
Cancer is the second most common cause of deaths in the United States, after 
heart disease, and it accounts for 1 in every 4 deaths [1]. Breast cancer is the number 
one most diagnosed cancer and the second cancer killer in women in the United 
States [2, 3] (Fig. 1). The majority of the deaths associated with this cancer, result 
from the ability of the cancer cells to invade the surrounding environment and spread 
to distant sites in the body. The 5-year survival rate of breast cancer falls from 98% 
for localized tumors to 23% for metastatic disease [4].   
 
 
Figure 1: Cancer death rates among females in the United States. Modified from cancer facts 
and figures. American Cancer Society 2014. 
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Breast cancer is a multi-step diseases characterized by abnormal growth and 
spread of cells. Its progression involves transformation, tumor growth, invasion, and 
metastasis. In breast cancer in particular, constitutive activation of oncogenes like Ras 
and ERBB2, and downregulation of tumor suppressor genes like p53, are known to 
lead to transformation of cells and initiate tumor growth [5-7]. A recent notable 
review article identified a set of hallmarks or traits necessary to prolong the 
progression of cancer. These include sustaining proliferative signaling, evading 
growth suppressors, resisting cell death, enabling replicative immortality, inducing 
angiogenesis, and activating invasion and metastasis [8]. It is evident however that 
additional changes to the tumor microenvironment (the cells, matrix, and soluble 
molecules that surround the tumor) coupled with pre-existing genetic deregulation 
allow cells to progress through other cancer stages, as gene expression patterns are 
more similar between invasive and non-invasive tumor cells when compared to 
normal cells [9]. To successfully invade, the breast cancer cell must break away from 
the primary tumor, degrade proteins associated with the extracellular matrix (ECM) 
and the basement membrane, and migrate through surrounding tissue to blood and 
lymphatic vessels. 
 
1.2 Stages of Breast Cancer 
The normal mammary gland contains epithelial cells organized into hollow 
ducts and enclosed by a continuous basement membrane. These structures 
communicate with the stroma environment [10] present just outside each duct. Ductal 
carcinoma in situ (DCIS) is a pre-invasive stage of cancer characterized by the 
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proliferation of malignant cells within the lumen of mammary ducts. In this tissue, the 
basement membrane is still intact; however, an increase in stroma associated cells is 
observed, along with the over-expression of oncogenes that play significant roles in 
cancer progression such as ERBB2 and c-myc [11]. In invasive ductal carcinoma 
(IDC) tissue, the mammary ducts have lost their characteristic basement membrane, 
and this in part allows for the transformed cells to invade into the stroma and 
ultimately metastasize to other organs.  
During cancer progression, the tumor microenvironment undergoes specific 
physiological changes that are categorized into distinct stages for clinical 
management. Stage 0 (also referred to as carcinoma in situ) is characterized by 
abnormal cell proliferation in the mammary duct (DCIS), lobules of the breast 
(LCIS), or nipple (Paget’s) [12]. In stage I, the tumor size is less than 2 cm and 
cluster of cancer cells may or may not be present in the lymph node. In stage II, the 
tumor size is between 2 and 5 cm but has not spread to the lymph nodes or the tumor 
size is below 2 cm and additional tumors below 2 mm are detected in 1 to 3 axillary 
lymph nodes. In stage III, the tumor is any size and has spread to at least 9 axillary 
lymph nodes or lymph nodes near the collarbone and breastbone. In stage IV, cancer 
cells have spread to other parts of the body most notably the lung, brain, bone and 
liver [13]. 
 
1.3 Current DCIS management 
DCIS is recognized as a late stage of cell deregulation and its histological 
patterns can vary from atypical hyperplasia to invasive breast cancer [14]. Increase 
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chromosomal imbalance, HER2 overexpression, p53 mutations, breakdown of the 
myoepithelial cell barrier, fibroblast proliferation, angiogenesis in the surrounding 
tissue [15-17] are among the numerous markers used to separate DCIS from normal 
tissue, atypical hyperplasia, and IDC. For example, loss of DNA heterozygosity is 
observed in 70% of high grade DCIS as opposed to 35-40% in atypical herplasia and 
0% in normal tissue [18]. Data however suggests that DCIS represents a stage of 
breast cancer development where most of the molecular changes associated with IDC 
have already occurred although the tumor itself has not assumed the malignant 
phenotype [19, 20]. 
Because of the large variations in clinical behavior described above, DCIS is 
recognized as a very heterogeneous disease. This heterogeneity hampers the pre-
identification of the 50% DCIS cases that never progress to IDC. Currently, there are 
four primary mode of treatment that are use to manage DCIS and prevent IDC. Up 
until the 1980s, mastectomy was the primary treatment [21]. However, due to the 
physical and psychological consequences associated with mastectomy, breast 
conserving surgery (also known as lumpectomy) has become the approach of choice 
in low-risk cases although mastectomy is still being used in 30-40% of cases [22]. 
Randomized clinical trials have identified that lumpectomy followed with radiation 
therapy can decrease the rates of local recurrence by 40-60% but this appears to be 
highly dependent on age, tumor size and molecular profiles [18, 23]. A fourth 
approach which combines lumpectomy with adjuvant therapy such as tamoxifen with 
or without radiation therapy has been developed for estrogen receptor positive DCIS 
[18].  
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Unfortunately, each of these treatment methods is accompanied by its share of 
side effects, emotional and psychological strain. One of the major hurdles in the 
management of DCIS is the issue of overtreatment especially in patients at low risk of 
developing IDC. The lack of proper understanding and identification of at risks 
markers has led the treatment of those DCIS patient that may not need treatment. For 
this reason, most patients diagnosed with DCIS are usually over-treated with harsh 
therapies even though the majority of these tumors never become lethal. The factors 
regulating the switch from localized to invasive breast cancer remain poorly 
understood and improving both disease survival and clinical management of patients 
will require understanding of the molecular mechanisms that regulate each of these 
steps and the identification of key factors at play.  
 
1.4 Factors contributing to breast cancer invasion 
HER2, a receptor tyrosine kinase, is over-expressed in more than 50% of 
DCIS cells and the risk of developing IDC from DCIS increases by 6-fold for cells 
overexpressing ERBB2 [24]. This increased invasion occurs via activation of 
members of the mitogen activated protein kinase (MAPK) and phosphoinositide-3 
kinase (PI3K) pathways [25, 26] (Fig. 2). PI3K/Akt and P38-MAPK are potently 
activated by environmental stresses [27] and control the expression of matrix 
metalloproteinases (MMPs). Members of the MMP family degrade the basement 
membrane and stromal extracellular matrix, a precursor to invasion and metastasis. 
However, not all ERBB2 expressing DCIS develop into IDC and patients whose 
DCIS never progresses to IDC have an almost 100% chance of survival [18, 28].  
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Figure 2: HER2 pathway along with known pharmacological inhibitors linked to their targets. 
 
 
Like most tissue, breast tissue is comprised of parenchyma and stroma, two 
distinct compartments that interact through molecular and mechanical signaling. The 
growth and progression of breast cancer is known to depend on both the malignant 
potentials of the cancer cells and their response to stroma-associated signaling in the 
tumor microenvironment [29]. Macrophages, endothelial cells, and fibroblast are all 
non-malignant stromal cells that clearly have been linked to cancer promotion [30-
35]. Stromal factors also contribute to initiation, growth, and spread of tumors. The 
implications of stroma cells in cancer have long been studied, and we know that 
normal fibroblast and mesenchymal cells provide signals to inhibit cancer cells 
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behavior while tumor associated fibroblasts enhance cancer progression [32]. These 
signals include differential expression of well known tumor suppressors and 
oncogenes such as ERBB2, p53 and PTEN in the fibroblast cells.  
Both compartments of the cancer microenvironment (stroma and epithelial) 
are evolving together, and their constant interactions during this evolution effects the 
outcomes of the disease. The role of fibroblasts in cancer progression in particular has 
been the focus of numerous studies in the past two decades. Fibroblasts are the most 
abundant cells in animal connective tissue and are primarily responsible for 
synthesizing the extracellular matrix and collagen. They are found to act both as 
tumor suppressors and tumor promoters [32]. Normal fibroblasts inhibit 
differentiation of normal epithelial cells where as cancer associated fibroblasts 
(CAFs) have the ability to induce morphological transformation of epithelial cells 
[36, 37]. One characteristic of CAFs is their similarity to myofibroblasts which are 
differentiated fibroblasts found most abundantly in sites of inflammation and wound 
healing and enhance tumor phenotypes like proliferation, invasion and migration [38]. 
CAFs are responsible for the secretion of key chemokines and growth factors such as 
CXCL12, hepatocyte growth factor (HGF) and TGF-β whose receptors are expressed 
on the surface of cancer cells. In so doing, CAFs influence primary tumor growth, 
invasion and metastasis [39]. In addition, signal cross-talk between CAFs and tumor 
cells have been shown to modify the tumor microenvironment extra-cellular matrix 
and basement membrane [39, 40]. Changes in matrix mechanical properties were 
found to suffice in inducing fibroblasts transformation to myofibroblasts [41]. In 
addition, a study by Fleming et al observed that primary fibroblasts cells from 
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Caucasian American patients induced bigger tumors in mice than fibroblast from 
African American patients [42]. This study presented a fibroblast specific gene profile 
associated with race suggesting cancer discrepancies to be involved both in the 
parenchyma and stroma cells. 
An important breakthrough in breast cancer research will be to uncover the 
factors, which along with genomic abnormalities, trigger DCIS to IDC transition. 
Identifying these factors will assist in tailoring patient-specific therapies given that 
current clinical management of DCIS has lead to over-treatment of patients who may 
never have developed IDC [43]. 
 
1.5 Epithelial to mesenchymal transition 
For invasion to occur, significant cellular transformation needs to take place 
especially in in vivo structures. Epithelial-to-mesenchymal transition (EMT) is a 
process where epithelial cells loose their distinctive morphology and molecular 
characteristics to acquire a mesenchymal motile phenotype that is often associated 
with invasion. This phenomenon is indispensable during embryogenesis and tissue 
remodeling. In order for gastrulation and organogenesis to occur, progenitor cells 
through EMT are able to loosen their cell-cell contact, detach and undergo intrinsic 
cell motility toward specific regions of the developing embryo [44]. Although 
normally dormant in adult tissue, EMT is sometimes reactivated during wound 
healing and tissue regeneration.  
 EMT is observed to occur during tumor development and likely plays a role in 
tumor progression [45, 46]. In tumors, this process is characterized by the loss of 
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epithelial baso-apical polarity and cell-cell junctions, gain of spindle morphology, and 
activation of transcription factors that lead to increased invasion [47, 48]. EMT is 
almost always initiated with increased expression of transcription factors (SNAIL 1, 
SLUG, ZEB, TWIST) that modulate the expression of E-cadherin, a protein important 
for the characteristic cell-cell adhesion observed in epithelial cells and the main 
component of cadherin junctions [49]. Along with decreased expression of E-
cadherin, EMT is coupled with increased expression of mesenchymal markers like 
vimentin, alpha smooth muscle actin, N-cadherin and fibronectin [48]. 
 The induction of EMT during tumor development is a consequence of external 
cues in the tumor microenvironment [50-52]. Several signaling pathways (Notch, β-
catenin), growth factors (EGF, TGF-β1, FGF) and hypoxia are known inducers of 
EMT. Along with its ability to induce migration and invasion in cells, EMT is 
demonstrated to generate cells with stem like properties which include the ability to 
self-renew and initiate tumor [53, 54]. and circulating stem cells have undergone 
EMT [55]. EMT has also been implicated in therapy resistance. In breast cancer, 
residual cells that survived chemotherapy were characterized by the expression of 
many EMT-associated genes [56] and these residual cells also share characteristics of 
tumor initiating cancer stem cells [57-59]. 
 
1.6 Interstitial fluid flow 
Cells in normal tissue are subject to forces that result from their interactions 
with other cells and the ECM. Changes in these forces can influence cellular survival, 
motility, gene expression, and differentiation [60]. In addition, there are 
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biomechanical consequences of tumor growth that enhance cancer progression. As 
the tumor grows and expands, a host of mechanical forces and physical properties of 
the tumor microenvironment are altered.  
Matrix stiffness [61], fluid pressure [62], matrix density [63], and interstitial 
fluid flow  (IFF) [62] (Fig. 3) are all altered during cancer progression. IFF in 
particular is higher in tumor tissue when compared to normal due to elevated 
interstitial fluid pressure [64].  
 
 
Figure 3: Interstitial fluid flow is defined as the movement of fluid within tissues. This fluid 
leakage originating from blood vessels is narmally drained in lymphatic vessels. 
 
Levels of IFF have been measured to range from 0.1 to 1 µm s-1 in normal 
tissue and 0.5 to 55 µm s-1 in tumor tissue [65-68]. This elevated IFF is driven by 
steep fluid pressure gradients at the tumor margin [69-72]. Increased IFF - caused by 
angiogenesis and lymphangiogenesis, and increased vascular permeability - has been 
correlated with lymph node metastasis in human carcinoma, increased cellular 
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organization and migration of tumor, fibroblast, endothelial, immune and 
mesenchymal stem cells [67, 68, 73-83]. In addition, IFF alters extracellular gradients 
of growth factors and chemokines. It is further associated with transporting antigens 
and other soluble factors to lymph nodes [82, 84], and applying forces directly to cells 
(via fluid shear) and indirectly via the matrix [85].   
To date, different studies have proposed mechanisms to explain the cell 
migration induced by elevated IFF, although most have focused on already-invasive 
cells. In fibroblasts, IFF induced myofibroblast differentiation and secretion of matrix 
metalloproteinases (MMPs), thus indirectly aiding tumor cell migration through 
matrix priming [41, 86]. Shieh et al showed that fluid flow enhances fibroblast 
migration via a mechanism dependent on transforming growth factor (TGF)-β1 and 
collagenase [26]. They proposed a model in which fluid flow causes stromal 
remodeling by fibroblast which facilitates tumor cell invasion. Shields et al 
demonstrated that fluid flow increased the metastatic potential of many cancer cell 
lines by creating a CCR7-dependent autologous chemotactic gradient around cells in 
3D [75, 86, 87] (Fig. 4). Polacheck et al identified yet another mechanism where IFF 
was shown to affect cellular fluid drag and matrix adhesions via integrins and focal 
adhesions, and interestingly leading to migration against the direction of flow [77, 
78]. In metastatic cells, IFF altered extracellular chemokine gradients to accelerate 
glioma cell migration via CXCR4 [75, 76, 78]. IFF was further demonstrated to 
modulate MMP activity through cell surface glycocalyx [79, 80, 88]. While we know 
some of its effects on the tumor microenvironment, the specific molecular pathways 
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triggered by interstitial fluid flow in tumor cells are still unclear, especially those that 
play a crucial role in initiating invasion in breast cancer cells. 
 
 
Figure 4: Consequences of interstitial fluid flow (IFF) in tumors. IFF has been shown lead the 
differentiation of fibroblasts into myofibroblasts, and to encourage tumor cells invasion by 
inducing fibroblast degradation of matrix and creating autologous chemotaxis. 
 
1.7 Outstanding questions 
Breast cancer invasion in general and the transition from DCIS to IDC in 
particular is a complex process regulated by a multitude of factors (EMT, tumor and 
stroma associated factors). While we know some of its effects on tumor and stromal 
cells, the specific molecular pathways triggered by elevated interstitial fluid flow in 
tumor cells are still unknown, especially those that may play a crucial role in 
initiating invasion in breast cancer tissue. Nevertheless, mechanical forces alone are 
likely not sufficient to cause invasion. Deregulation at the gene level and changes in 
tumor-stromal interactions may all play a part to increase invasion, all driven by 
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elevated interstitial fluid flow. The goal of this project is to elucidate the role these 
different components play in the transition from non-invasive breast cancer to 
invasive disease. Although much attention has been given to the tumor 
microenvironment and its potential application in cancer therapy, more work is 
needed to unveil the factors of the microenvironment that are key players in the 
transition from DCIS to IDC.  
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CHAPTER 2: Interstitial fluid flow-induced invasion is 
HER2 independent 
2.1 Introduction 
 Cancer is a multi-step disease and its progression involves transformation, 
tumor growth, invasion, and metastasis. Breast cancer is the second-leading cause of 
cancer-associated deaths in women and its mortality is predominantly due to the 
metastasis of cancer cells. For metastasis to occur, cells have to develop an ability to 
invade the surrounding stroma, migrate to distant sites, and survive in foreign 
environments. Several factors have been identified as regulating cancer cell invasion 
and metastasis. Genetic mutations such as HER2 amplification and overexpression 
[89, 90] along with mechanical changes to the tumor microenvironment [91, 92] are 
factors that have each been correlated with breast cancer invasion but are rarely 
studied in combination. 
ERBB2 is an oncogene that encodes for the receptor tyrosine kinase HER2, a 
protein known to increase the aggressiveness of breast cancer [93]. Poor breast cancer 
prognosis has been correlated with the overexpression of HER2 in 15-30% [94, 95] of 
all human breast cancers. In addition, HER2 is overexpressed in more than 50% of 
ductal carcinoma in situ (DCIS) cells – a pre-invasive stage of breast cancer. The risk 
of developing invasive ductal carcinoma (IDC) from DCIS is six times higher when 
cells overexpress HER2 [24]. The therapies currently used to treat DCIS patients tend 
to vary depending on the receptor profile of the cells. They usually include 
mastectomy, lumpectomy followed with radiation therapy and hormone therapies. 
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However, approximately 30% of patients who are diagnosed with DCIS will develop 
invasive breast cancer despite these harsh therapies [18, 93]. 
Interstitial fluid flow (IFF), which is defined as the movement of fluid through 
the tissue, is elevated in tumors compared to normal tissue [66, 67]. IFF was 
previously shown to induce tumor, fibroblast, and endothelial cells migration [75, 76, 
78, 83]. While we know some of its effects on tumor and stromal cells, the specific 
molecular pathways triggered by elevated interstitial fluid flow in tumor cells are still 
poorly described, especially those that aid in initiating invasion of breast cancer cells 
in combination with altered gene expression profiles. Specifically, the combined role 
HER2 expression and interstitial fluid flow play on invasion has never been studied, 
particularly in the context of how they may influence progression at different stages 
of breast cancer.  
 We hypothesized here that interstitial fluid flow induces invasion of HER2 
positive breast cancer cells by supporting the activation of the HER2 pathway and 
causing increased downstream signaling of important intracellular signal transducers 
such as phosphoinosite-3-kinase (PI3K). Identifying the combined roles of interstitial 
fluid flow and Her2 expression in breast cancer invasion will expand our 
understanding of why some cancers progress though invasion and metastasis and 
other do not. 
 
2.2 Methods 
Cell Culture 
  
19 
 
To model normal breast epithelium, DCIS, and IDC, we used a previously 
developed model of breast cancer based on MCF-10A human mammary epithelial 
cells engineered to overexpress HER2 [96, 97]: MCF-10A human mammary 
epithelial cells, MCF-10As retrovirally transduced with wild-type ERBB2 (NeuN) and 
MCF10A overexpressing a constitutively active mutant of ERBB2 (NeuT). When 
cultured in 3D conditions, these cells exhibit behavior of normal (MCF10A), pre-
invasive ERBB2 positive (NeuN) and invasive (NeuT) cancer phenotypes [96, 97]. 
These cells were maintained in DMEM/F12 supplemented with 5% donor horse 
serum (Atlanta Biologicals, Atlanta, GA), 20 ng/ml epidermal growth factor (EGF) 
(Peprotech, Rocky Hill, NJ), 10 µg/ml insulin (Sigma-Aldrich, Saint Louis, MO), 100 
ng/ml cholera toxin (Enzo Life Sciences, Farmingdale, NY), 500 ng/ml 
hydrocortisone (Sigma Aldrich), and 1% penicillin/streptomycin (Mediatech, 
Herndon, VA). Cell lines naturally expressing HER2 were also used: BT474, MDA-
MB-453 and SKBR3. BT-474 and MDA-MD-453 cells (ATCC, Manassas, VA) were 
grown in DMEM (Mediatech) supplemented with 10% fetal bovine serum (FBS) 
(Atlanta Biologicals) and 1% penicillin/streptomycin. SKBR3 cells were grown in 
McCoy’s 5A (Mediatech) supplemented with 10% FBS and 1% 
penicillin/streptomycin. All cells were maintained in a humidified environment at 
37oC and 5% CO2. 
 
EGF Chemoinvasion 
50 µl of 50% growth-factor-reduced Matrigel solution was coated on 
transwell membranes and allowed to gel at 37oC for 2 hours. Cells were resuspended 
in basal media 20,000 cells total was added to each culture inserts. Basal media 
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(control) or 1 ng/ml EGF media was added below the transwell membranes. After 24 
hours, cells on the upper side of the culture insert were removed with cotton swabs. 
Cells on the underside of the cell culture insert were fixed, stained and counted as 
described below for the 3D-invasion assay. Chemoinvasion was measured by 
counting the number of cells that invaded through the matrix and migrated across the 
porous membrane. Experiment was repeated at least twice with 3 replicates each time. 
 
3D Invasion Assay 
 Interstitial fluid flow was applied to cells as previously described [75, 86, 98]. 
Briefly, single cells were embedded in a matrix composed of 1.3 mg/ml rat tail tendon 
collagen type I (BD Biosciences, San Jose, CA) and 1 mg/ml Matrigel™ basement 
membrane matrix (BD Biosciences) at a final concentration of 5 x 105cells/ml inside 
culture inserts with 8 µm diameter pores (Millipore, Billerica, MA). For static 
(control) conditions, serum-free media levels inside the insert and outside in the well 
were kept approximately equal, resulting in minimal pressure difference across the 
gel and no interstitial flow. For IFF conditions, serum-free media was added under 
the insert (100 μl) and above the gel (650 μl). The pressure difference generated by 
these volumes is approximately 1.3 cm H2O (or 1 mm Hg). After 24 hours of either 
physiological interstitial flow (approximate flow velocity ~0.1 µm/s) or static 
conditions, invasion was measured by counting the number of cells that invaded 
through the matrix and migrated across the porous membrane. Migrated cells on the 
underside of the culture insert membranes were fixed in 4% paraformaldehyde in PBS 
for 30 min and permeabilized with 0.5% Triton X-100 in PBS for 10 min. Cells were 
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then stained with Alexa Fluor 488-conjugated phalloidin (1:50) (Life Technologies) 
and 4′,6-diamidino-2-phenylindole (DAPI) (1:500) (MP Biomedicals, Santa Ana, 
CA). Fluorescence was visualized on a widefield fluorescence microscope (Leica 
Microsystems). DAPI-stained nuclei on five randomly selected locations of each 
membrane were counted. Phalloidin stain was used to confirm positive DAPI stains 
corresponded to cells. Percent invasion was calculated with the following equation: 
 
 llsSeededNumberofCeageArea
rfaceAreaMembraneSulCountAverageCel
Invasion
*Im
**100
%   
 Experiments were repeated at least twice with a minimum sample size of n=3.  
 
Western Blotting 
Following the invasion assay, total and phospho-protein levels were 
determined by western blot. Cells were isolated using 2.5mg/ml collagenase D 
(Roche, Indianapolis, IN) for 30 minutes. The resulting solution was centrifuged, and 
the pellet was washed with PBS and resuspended in RIPA lysis buffer (150 mM 
NaCl, 1% NP40, 0.5% DOC, 50 mM Tris-HCl at pH 8, 0.1% SDS, 10% glycerol, 5 
mM EDTA, 20 mM NaF and 1 mM Na3VO4). Lysates were then cleared via 
centrifugation at 16,000 x g for 20 minutes at 4°C. The antibodies used were: rabbit 
polyclonal anti-phospho PI3K and total PI3K (1:500, Cell Signaling, Danvers, MA), 
rabbit polyclonal anti-β-actin (1:3000, Cell Signaling), anti-HER2 (1:1000, Cell 
Signaling), rabbit polyclonal anti-phospho and total epidermal growth factor receptor 
(EGFR) (1:500, Abcam), goat anti-rabbit IgG conjugated to horseradish peroxidase 
(HRP) (1:10000, Abcam). 
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Data and Statistical Analysis  
Data are expressed as mean ± standard error of the mean. Differences among 
treatment groups were tested using Student’s t-tests (for two groups) or two-way 
analysis of variance (ANOVA) (for three or more groups) as appropriate using 
GraphPad Prism. When ANOVA identified a significant difference, a Bonferroni 
post-test was employed for multiple comparisons. Differences were accepted as 
significant at p < 0.05. 
 
2.3 Results 
EGF induces invasion of MCF10A and NeuN 
We relied primarily on MCF10A, NeuN, and NeuT as our breast cancer 
model. The main difference between these cells lies in their expression of HER2. 
MCF10A are nontumorigenic mammary epithelial cells. NeuN and NeuT are cell 
lines deriving from MCF10A that overexpress wild type HER2 and mutant HER2 
respectively. All 3 cells lines express similar levels of the other HER family member 
EGFR (Fig. 5A). In addition, each cell line represents a specific stage of breast cancer 
progression primarily as a consequence of their HER2 expression (MCF10A: normal-
like, NeuN: DCIS-like, NeuT: IDC-like), which is a known inducer of invasion in 
cells [89, 99, 100]. The invasion capability of the cell lines is demonstrated in Fig. 
5B. Using an EGF-dependent chemotaxis assay, the cells were plated on top of a 
layer of reconstituted basement membrane matrix (Matrigel) and 1 ng/ml EGF was 
added to the underside of the cell culture insert as a chemoattractant. We observed 
that MCF10A cells only invaded in the presence of EGF. NeuN cells also responded 
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to the EGF gradient with a 10-fold increase of invasion; however NeuT cells were 
insensitive to EGF, exhibiting a high level of invasion in the absence of any external 
stimulus.  
 
 
Figure 5: EGF induces invasion of MCF10A and NeuN: The cell lines used in this study model 3 
separate staged of breast cancer, normal, HER2 positive pre-invasive and HER2 positive 
invasive cells. A) Representative western blot of epidermal growth factor family family members 
HER1 (commonly known as EGFR) and HER2 (Neu). All 3 cell lines express HER1, however 
detectable levels of HER2 were only observed in NeuN and NeuT. β actin was used as loading 
control. B) EGF induces invasion of the non-invasive cells MCF10A and NeuN but does not 
affect NeuT invasion. Chemotaxis assay: cells were seeded on a layer of matrigel in a cell culture 
insert. 1ng/ml EGF was added to the underside of the cell culture insert as a chemo-attractant. 
Invasion was measured after 24 hours by counting the number of cells that migrated and 
invaded through the matrigel and pores of the cell culture insert. Experiment was run in 
triplicates. All values are mean ± SEM. Student t test (**: p < 0.01) 
 
 
Interstitial fluid flow induces invasion of both HER2 positive and negative cells. 
Using our 3D IFF invasion assay, we measured the effects of IFF on invasion 
(See appendix figures). Invasion was significantly greater in flow conditions 
compared to static in parental MCF10A and MCF10A cells overexpressing HER2 
(NeuN and NeuT) (Fig. 6). We further verified the IFF response of breast cancer cell 
lines with natural HER2 overexpression (SKBR3, MDA-MB-231 and BT-474) and 
again observed increased invasion under IFF (Fig. 6). The only HER2 negative cell 
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line in the panel of cells was MCF10A, and these cells exhibited low basal (static) 
invasion compared to NeuN and NeuT. This was expected given that these are non-
tumorigenic epithelial cells and the previously described role of HER2 in breast 
cancer invasion [89]. Based on the observed effect of EGF on MCF10A invasion and 
EGF’s previously observed role in invasion [101-103], we decided to look at the role 
of EGF and its receptor EGFR on IFF-induced invasion of MCF10A. 
 
 
Figure 6: Interstitial fluid flow increases invasion of HER positive and negative cells. Percent 
invaded cells after 24 hours in 3-D IFF assay using our breast cancer model cells and additional 
HER2 overexpressing cell lines. All values are mean ± SEM. Student t test (*: p < 0.05; **: p < 
0.01, ***: p < 0.001), n>12. 
 
EGFR activity is necessary for interstitial fluid flow induced invasion in MCF10A.   
 Parental MCF10A cells do not express detectable levels of HER2, however 
they do express EGFR (Fig. 5A). The observation that MCF10A invaded in the 
presence of EGF and/or IFF led us to block EGFR using the pharmacological 
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inhibitor AG1478 in our 3-D invasion assay. When blocking EGFR, we observed a 
significant decreased in IFF-induced invasion of the cells (Fig. 7A), suggesting that 
EGFR is required for IFF induced invasion in these cells. A key member of the 
molecular pathway activated by IFF in cells to induce invasion is PI3K (see chapter 4 
for further discussion). The regulatory subunit of PI3K (p85) is almost always 
phosphorylated in the presence of IFF, however its modulator was not identified in 
MCF10A. IFF-induced PI3K phosphorylation was significantly decreased in these 
cells when treated with AG1478 (Fig. 7B), suggesting that EGFR activation is 
upstream of PI3K phosphorylation in IFF-induced invasion of MCF10A cells.   
 
 
Figure 7: EGFR activity is necessary for flow induced invasion in MCF10A. A) Changes in flow-
induced invasion in the presence or absence of EGFR (HER1) inhibitor (AG1478) in MCF10A. 
B) Representative western blot of phospho-p85 after 24 hours in 3D invasion assay with and 
without the AG1478; β actin was used as loading control. All values are mean ± SEM. Student t 
test and 2-way ANOVA (*: p < 0.05; **: p < 0.01, ***: p < 0.001), n>6. 
 
EGFR and HER2 are not necessary for IFF-induced invasion in NeuN and NeuT 
In contrast, blocking EGFR or HER2 with AG1478 and/or lapatinib did not 
significantly alter IFF-induced invasion in NeuN and NeuT. In NeuN, both EGFR and 
HER2 are necessary for static invasion because in the presence of these inhibitors, 
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static invasion was ablated (Fig. 8). However, IFF-induced invasion was still 
pronounced in the presence of one or both inhibitors. EGFR and HER2 are known to 
induce random invasion in cells, which is initiated by the heterodimerization of both 
receptors. The fact that IFF is still able to enhance NeuN invasion in the presence of 
inhibitors to both HER2 and EGFR suggests that IFF-induced invasion occurs 
independently of these receptors in these cells.  IFF induced invasion in NeuT is also 
independent of these receptors (Fig. 8), despite HER2 being constitutively 
phosphorylated in these cells (Fig. 5A). 
 
 
Figure 8: EGFR and HER2 activity are not necessary for flow induced invasion in NeuN and 
NeuT. A) Changes in invasion in response to HER1 and HER2 inhibitors in NeuN. NeuN 
response to AG1478, Lapatinib or both; neither inhibitors ablated IFF response. B) Changes in 
invasion in response to HER1 and HER2 inhibitors in NeuT. Neither inhibitors ablated IFF 
response. All values are mean ± SEM. Student t test (*: p < 0.05. *: p < 0.05; **: p < 0.01, ***: p 
< 0.001); n>6. 
 
 Furthermore, IFF does not alter activation of HER2 as seen by the lack of 
change in phosphorylation of HER2 when comparing NeuN cells exposed to flow and 
control static conditions (Fig. 9A). In addition western blots of total HER2 protein in 
the presence of the HER2 inhibitor, lapatinib, revealed that although this inhibitor 
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decreased total levels of HER2, it did not alter the increased PI3K phosphorylation 
observed in IFF samples (Fig. 9B).   
 
 
Figure 9: Inhibiting HER2 does not alter flow induced activation of PI3K. A) Representative 
western blot of phosphorylated and total HER2 in MCF10A, NeuN, and NeuT. β actin was used 
as loading control. HER2 is constitutively phosphorylated in NeuT and IFF does not activated 
HER2 phosphorylation in NeuN. B) IFF induces phosphorylation of PI3K regulatory subunit 
p85 and this is achieved independent of HER2. Representative western blot of total HER2, 
phosphor PI3K in the presence of HER2 inhibitor (Lapatinib). Inhibiting HER2 (upstream of 
PI3K) or mtor (downstream of PI3K) do not alter flow induced activation of PI3K, further 
supporting our claim that IFF induced invasion is independent of HER2 in NeuN and NeuT. 
 
2.4 Discussion 
In this study we characterized the role of EGFR and HER2 in regulating 
interstitial fluid flow induced invasion in MCF10A, NeuN and NeuT, three cells lines 
exhibiting distinct invasion patterns and modeling three separate stages of breast 
cancer. EGFR inhibition prevented both IFF induced invasion and phosphorylation of 
PI3K in MCF10A. In contrast, both EGFR and HER2 inhibition decreased invasion 
of static (control) NeuN and NeuT but did not alter IFF-induced invasion and PI3K 
activation. 
  
28 
 
In MCF10A, a non-tumorigenic cell line, we observed invasion was strongly 
dependent on EGFR, a growth factor receptor whose signaling is tightly controlled in 
normal tissue. In these cells, invasion was only observed when EGF was added to the 
system or in the presence of IFF. EGFR was identified as the activator of IFF-induced 
PI3K (Fig. 7). In addition, these cells lost their IFF-induced invasion when EGFR was 
inhibited. The fact that IFF was able to induce a low but significant increase in 
migration and invasion in these cells was shown in a previous study [75], however a 
mechanism was never identified. EGFR is the most studied membrane tyrosine kinase 
receptor in cancer. Mutations and over amplifications of this receptor have long been 
implicated in most cancer initiation and progression [103-105]. The most commonly 
demonstrated mode of IFF induced invasion is autologous chemotaxis, in which IFF 
creates a chemokine gradient around the cells allowing them to migrate in the 
direction of flow. However, when endogenous levels of EGF was added to MCF10A 
in the presence of IFF in order to ablate all peripheral cellular gradients, the cells 
invaded more in response to IFF suggesting that MCF10A do not respond to IFF 
through an EGF-dependent autologous chemotaxis. In contrast, we hypothesize that 
IFF may induce EGF production in cells or indirectly activate EGFR in an EGF-
independent manner. Although this was not tested in our current study, additional 
experiments are underway. Nonetheless this strongly suggests the potential role IFF 
may play in EGFR-dependent cancers, an area that has never been examined, and 
further studies may be beneficial in improving therapeutic intervention of this type of 
cancer.  
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The combined role of members of the epidermal growth factor receptor family 
in breast cancer invasion, especially EGFR and HER2, has been explored in these and 
other cells [28, 89, 100, 106-109] but never in the context of IFF. HER2 is an 
established regulator of invasion in breast cancer cells. Its activity is usually regulated 
by heterodimerization with its other family members (EGFR, HER3 and HER4) and 
together, they transactivate key kinases necessary for the transcription of genes 
associated with cell motility [101, 108]. Although it has previously been shown that 
IFF plays a role in cancer invasion [41, 75, 78, 86], the molecular mechanisms 
underlying its effects on cells are still poorly understood. We initially hypothesized 
that IFF in combination with HER2 induced invasion. The data presented in this study 
strongly suggest that although HER2 is necessary for most invasion in HER2 positive 
cells, IFF induces a pathway independent of HER2 and these pathways will be 
presented in great details in the following chapters. 
 This study further reveals that IFF may play a role in HER2 drug resistance 
since HER2 positive breast cancer cells can still invade even when treated with anti-
HER2 therapies, given the lack of HER2 involvement in IFF induced invasion. 
Regardless, HER2 overexpression still modulates significant gene expression changes 
in cells and these persistent changes may affect IFF response, even if HER2 
activation at that moment does not. 
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CHAPTER 3: Interstitial fluid flow induces epithelial to 
mesenchymal transition in cells 
3.1 Introduction 
The tumor microenvironment includes a variety of biophysical forces whose 
effects are known to influence cancer progression. Interstitial fluid flow (IFF) is one 
such force that is present in normal breast tissue and elevated in tumors. We 
previously demonstrated that IFF induces invasion of normal, pre-invasive, and 
invasive cells via activation of phosphoinositide-3-kinase (PI3K). This phenomenon 
was observed both in single cells and in 3D acini structures. In normal cells, IFF-
induced PI3K activation was modulated by EGFR, a growth factor whose signaling is 
tightly controlled in normal tissue. In invasive cells, CXCR4 controlled IFF-induced 
invasion. In order to understand why different pathways are activated by IFF to 
enhance invasion in these cells, we questioned the role of epithelial-to-mesenchymal 
transition (EMT). EMT is a process observed in cancer progression where cells lose 
their epithelial characteristics and adopt a mesenchymal phenotype, which notably 
includes an increased propensity to invade.  
In this study, we employed two separate approaches to determine if interstitial 
flow affects the EMT process. In the first approach, we profiled mRNA and protein 
expression differences of cells after 24 hours of exposure to IFF. In the second 
approach, we developed a method to isolate the population of cells that consistently 
invaded after three serial exposures to IFF. We compared the levels of EMT markers 
in these cells to those of regular cells and those isolated from three consecutive 
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invasion assays under static conditions. We further profiled the morphological and 
cellular proliferation differences between these three groups. 
 
3.2 Methods 
Cell Culture 
Non-invasive and non-tumorigenic cells MCF10A, pre-invasive NeuN, and 
invasive NeuT cells were used. Cells were maintained in DMEM/F12 supplemented 
with 5% donor horse serum (Atlanta Biologicals, Atlanta, GA), 20 ng/ml epidermal 
growth factor (EGF) (Peprotech, Rocky Hill, NJ), 10 µg/ml insulin (Sigma-Aldrich, 
Saint Louis, MO), 100 ng/ml cholera toxin (Enzo Life Sciences, Farmingdale, NY), 
500 ng/ml hydrocortisone (Sigma Aldrich), and 1% penicillin/streptomycin 
(Mediatech, Herndon, VA).  
 
3D Invasion Assay 
 To isolate interstitial fluid flow responsive cells and static control, cells were 
embedded in a matrix composed of 1.3 mg/ml rat tail tendon collagen type I (BD 
Biosciences, San Jose, CA) and 1 mg/ml Matrigel™ basement membrane matrix (BD 
Biosciences) at a final concentration of 5 x 105 cells/ml inside culture inserts with 8 
µm diameter pores (Millipore, Billerica, MA). For static (control) conditions, serum-
free media levels inside and outside the insert were kept approximately equal, 
resulting in a minimal hydrostatic pressure difference across the gel and no 
measurable interstitial flow. For IFF conditions, serum-free media was added under 
the insert (100 μl) and above the gel (650 μl). The hydrostatic pressure difference 
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generated was approximately 1.3 cm H2O (or 1 mm Hg). After 24 hours of either 
physiological interstitial flow (approximate flow velocity ~0.1 µm/s) or static 
conditions, invasive cells were defined as the cells that invaded through the matrix, 
migrated across the porous membrane, and attached to the underside of the 
membrane. Gels and cells on the upper surface of the membrane were removed with 
cotton swabs. Migrated cells on the underside of the culture insert membranes were 
washed once in PBS then incubated in trypsin for 10-20 minutes. Detached cells were 
then resuspended in full media. The resulting solution was spun down for 5 minutes 
at 1,000 rpm and plated in a 24 well plate. Once the invaded cells were expanded to 
an appropriate cell concentration, the experiment was repeated two additional times to 
ensure the resulting population was primarily made of cells that are highly responsive 
to IFF. To check for increased IFF induced invasion, cells in similar 3D invasion 
assay conditions were run in parallel. The migrated cells in this condition were fixed 
in 4% paraformaldehyde for 30 minutes and stained with 4′,6-diamidino-2-
phenylindole (DAPI) (2 ug/ml) (MP Biomedicals, Santa Ana, CA). Labeled cells 
were visualized on a widefield fluorescence microscope (Leica Microsystems). 
DAPI-stained nuclei on five randomly selected locations of each membrane were 
counted. Phalloidin stain was used to confirm that positive DAPI stain corresponded 
to cells. Percent invasion was calculated with the following equation: 
 
 llsSeededNumberofCeimageArea
rfaceAreaMembraneSulCountAverageCel
Invasion
*
**100
%   
 
Western Blot 
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Following the 3D invasion assay, protein levels were determined by western 
blot. Cells were isolated from the matrix using 2.5 mg/ml collagenase D (Roche, 
Indianapolis, IN) for 30 minutes. The resulting solution was centrifuged, and the 
pellet was washed with PBS and resuspended in RIPA lysis buffer containing 
protease inhibitors (150 mM NaCl, 1% NP40, 0.5% DOC, 50 mM Tris-HCl at pH 8, 
0.1% SDS, 10% glycerol, 5 mM EDTA, 20 mM NaF and 1 mM Na3VO4). Cell grown 
on 2D cell culture flasks were trypsinized, washed twice in PBS and resuspended in 
RIPA lysis buffer containing proteases inhibitors (Roche). Lysates were cleared via 
centrifugation at 16,000 x g for 20 minutes at 4°C. Antibodies used were: rabbit 
polyclonal anti-β-actin (1:3000, Cell Signaling), rabbit monoclonal anti-vimentin 
(1:1000, Abcam), rabbit monoclonal anti-E-cadherin (1:1000, Abcam), rabbit 
polyclonal anti-collagen type IV (1:1000, Abcam), and goat anti-rabbit HRP 
(1:10000, Abcam). 
 
Immunofluorescence microscopy 
For visualization of vimentin expression differences, cells were plated onto 8 
well chamber slides at 10,000 cells per well. After 16 hours, cells were fixed in 4% 
paraformaldehyde in PBS for 30 minutes and permeabilized with 0.5% Triton X-100 
in PBS for 10 minutes. This was followed by 1 hour in blocking solution (1% BSA, 
0.1% goat serum). Cells were stained with rabbit monoclonal anti-vimentin (1:100) 
(Abcam) for 16 hours, washed in PBS 3 times. DAPI (2 ug/ml), and then incubated 
with Alexa Fluor 555 conjugated anti-rabbit IgG for 16 hours, followed by 3 more 
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washes in PBS. Fluorescence was visualized on a widefield fluorescence microscope 
(Leica Microsystems). 
 
Quantitative RT-PCR 
Quantitative RT-PCR (qRT-PCR) was performed on cDNA reversed 
transcribed using QuantiTech Reverse Transcription kit and QuantiTech SYBR Green 
PCR kit (Qiagen). Primers for epithelial markers human desmoplakin and integrin 
subunit α6 (Quantitech, Qiagen) were used to quantify mRNA expression differences 
between static and flow samples. 
 
Cell proliferation assay 
We performed an MTT colorimetric proliferation assay to determine 
differences in cellular proliferation and response to HER2 associated drugs. Cells 
were plated in 96-well plates (5,000 cells/well) with full media. Twenty-four hours 
after cell plating (day 0), media was changed to serum free treatment media 
(lapatinib, PD168393, control) and full media for each condition. Following the 
appropriate treatment period (1, 2, 3, 4 days), MTT reagent was added to each well 
and incubated for 4 hours. DMSO was used to dissolve the crystals and optical 
density readings at 570 nm were obtained using a spectrophotometer.   
 
Data and Statistical Analysis  
Data are expressed as mean ± standard error of the mean. Differences among 
conditions were tested using Student’s t-tests (for two groups) or two-way analysis of 
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variance (ANOVA) (for three or more groups) using GraphPad Prism. When 
ANOVA identified a significant difference, a Bonferroni post-test was employed for 
multiple comparisons. Differences were accepted as significant at p < 0.05. 
 
3.3 Results 
We previously identified that IFF increases invasion on non-invasive cells 
(see Chapter 2). In the current study, we hypothesized that one of the ways IFF 
increases invasion of cells is by inducing EMT in pre-invasive cells. During EMT, 
cells lose their epithelial characteristics, which include loss of junction proteins such 
as E-cadherin [49, 110]. We therefore compared gene expression changes in NeuN 
cells exposed to IFF for 24 hours and control. Using this approach, we observed that 
IFF significantly lowered the levels of desmoplakin, a junction protein and integrin 
alpha 6, a part of the α6β1 and α6β4 receptors that bind laminin V (a basement 
membrane protein) (Fig. 10A). In addition, we observed increased expression of the 
mesenchymal cells marker vimentin in lysates from IFF samples of both NeuN and 
MCF10A (Fig. 10B-C). 
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Figure 10: IFF induces the expression of EMT markers.  A) RT PCR revealed IFF-dependent 
decreased mRNA expression of desmoplakin and integrin alpha 6, two genes highly expressed in 
epithelial cells. B) Western blot analysis shows vimentin levels are increased in both NeuN and 
MCF10A cells after exposure to IFF.  
 
Collagen type IV is well studied as being one of the main protein components 
of the basement membrane [111, 112] where its expression is negatively correlated 
with breast cancer progression [113, 114]. It has however been recently identified as a 
positive EMT marker in mammary cells [115]. We questioned changes in the levels 
of this protein in MCF10A and NeuN and observed increase levels in the IFF 
conditions compared to control static conditions. Collagen IV levels increased in the 
presence of IFF in all cells tested (Fig. 11). In MCF10As, IFF-induced increase of 
collagen IV was ablated by the EGFR inhibitor AG1478. This inhibitor was 
previously demonstrated to reduce IFF-induced invasion (see chapter 2). Furthermore 
we observed that 3D spheroids of MCF10A and NeuN exposed to IFF also had an 
increased expression of collagen IV. This suggests that collagen IV plays similar 
roles in IFF signaling in both single cells and higher 3D complex structures. We 
previously identified that flow induced signaling occurs through EGFR in MCF10A 
  
37 
 
cells (Chapter 2). In line with this finding, we observed that the EGFR inhibitor 
AG1478 decreases collagen type IV levels in response to IFF (Fig. 11).  
 
 
Figure 11: IFF increases protein levels of intracellular collagen type IV. Western blot analysis of 
MCF10A single cells in the presence or absence of EGFR inhibitor AG1478 as well as MCF10A 
and NeuN spheroids. 
 
Although short exposure (24 hours) to IFF induced changes in expression of 
some EMT markers, the expression of key EMT-associated proteins like E-cadherin 
remained unchanged. For this reason we hypothesized that long term exposure to IFF 
is required for further EMT to occur. Following a new approach to isolate NeuT and 
NeuN population of cells that consistently invaded after three separate IFF invasion 
assay, we compared the expression of EMT markers in these cells (HF) to that of cells 
that consistently invaded under static conditions (HS). We tested changes in invasion 
after the isolation and observed that NeuT HF cells tended to become more invasive 
with more isolation rounds (Fig. 12) however this was not observed in NeuN HF.  
 
  
38 
 
 
Figure 12: NeuT cells at each cell sorting stage became more and more invasive. HF0: invasion 
assay of regular NeuT, first round of cell sorting; HF1: second round of cells sorting; HF2: third 
round of cell sorting. Error bars represent SEM of 3 replicates; *p value < 0.05; **p value < 0.01. 
 
NeuN HF cells exhibited lower levels of the epithelial marker e-cadherin (Fig. 
13A). Levels of the mesenchymal marker vimentin were usually low in NeuN, 
localized in distinct area in the cells, not filamentous, and with no clear network. As 
cells undergo EMT, just as what is observed during treatment with the known EMT 
inducer transforming growth factor TGF-β1, the expression and localization of 
vimentin changes. In EMT cells vimentin levels increases and adopt a more uniform 
filamentous network throughout the cell (Fig. 13B). And this has been observed in 
other cells lines and systems [116-118]. We observed that compared to their static 
(HS) counterparts, NeuN HF cellular distribution of vimentin also became uniform 
like in NeuT (Fig. 13C). The cellular localization of vimentin also changed. In regular 
NeuN cells, vimentin intensity was lower and localized in distinct sections of the cell 
surrounding the nucleus. In HS cells, although vimentin intensity was higher, it 
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remained localized in distinct sections of the cell surrounding the nucleus. In contrast, 
vimentin intensity of HF cells was higher than regular cells and spread out uniformly 
throughout the cell. 
 
 
Figure 13: Flow responsive cells express higher levels of EMT markers. Static (HS) and flow 
(HF) responsive cells were isolated following a series of 3 cells sorting. A) NeuN HS cells express 
lower levels of E-cadherin compared to HF cells. White bar represents 100 µm B) NeuN EMT 
induction (TGF-β1) leads to increase vimentin levels along with uniform cellular distribution C) 
HF cells express similar vimentin distribution when compared to NeuT, a cell that has 
undergone EMT. White bar represents 50 µm. 
 
A correlation between EMT and drug resistance has been established [119-
121]. Mesenchymal-like cells are usually more tolerant of drug treatments compared 
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to their more epithelial-like counterparts [122, 123]. For this reason, we also aimed to 
identify the potential role IFF-induced EMT may play on resistance to HER2 therapy 
by comparing cell proliferation of HF, HS and Reg in the presence of known breast 
cancer drugs. While relying primarily on MTT assays, we first observed a significant 
decrease in proliferation of HF cells compared to regular and HS cells (Fig. 14A). 
Although both inhibitors significantly affected cellular viability of all three cell types, 
HF cells exhibited a lower sensitivity to both drugs by HF cells (Fig. 14B). 
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Figure 14: NeuN HF cells proliferate less and have a higher tolerance to drug treatment 
compared to their regular and HS counterparts. A) HF cells proliferate at a slower rate than HS 
and reg cells. Values where normalized to day 0 values. B) HF cells survived more in the 
presence of lapatinib and PD168393, 2 EGFR and HER2 inhibitors. Values where normalized to 
day control Error bars represent SEM of 2 separate experiments with 4 replicates each. 
 
  
3.4 Discussion 
In this study, we followed two separate approaches to study the role of EMT 
in IFF-induced invasion. In the first approach, we focused on changes to EMT 
markers due to short exposure to IFF. In the second approach, we aim to identify the 
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consequences of longer exposure to IFF. Both approaches revealed that IFF induces 
EMT in cells. In addition, the second approach revealed that IFF renders cells 
resistant to HER2 positive breast cancer therapies. Our data further suggest the 
classification of intracellular collagen type IV as an EMT marker. 
We observed increased levels of vimentin and changes in vimentin filaments 
characterizations both after short and long IFF exposures. Vimentin filaments 
modulate cellular motility and invasiveness [124]. The fact that IFF enhances 
vimentin expression in cells further supports its role in cancer invasion. Loss of E-
cadherin was only observed in cells after longer exposure to IFF. During EMT, the 
levels of E-cadherin are regulated both at the transcriptional level by transcription 
factors like Snail and Slug and at the post-translational level by focal adhesion 
kinases (FAK), SRC and receptor tyrosine kinases [49]. Using pharmacological 
inhibitors, we previously concluded that FAK, SRC and receptor tyrosine kinases 
such as EGFR and HER2 are not involved in IFF-induced invasion of NeuN since 
they did not affect IFF-induced invasion. In line with these findings, the post-
translational regulation of E-cadherin was not expected. Because 24 hours may not be 
enough time to observe protein changes due to transcriptional regulation, this may 
explain why we only observed changes in E-cadherin levels when cells were 
repeatedly exposed to IFF (Fig. 13).  
The role of collagen type IV in EMT is not clear and merits further 
investigation. We identified collagen IV to be up-regulated in correlations with EMT 
in cells exposed to IFF (Fig. 11) and this agrees with a recent findings where it was 
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identified as an EMT inducer [115]. Collagen IV has however been more correlated 
with basement membrane as it one of the main components after Laminin V.  
Several studies have demonstrated a close connection between EMT and drug 
resistance [125, 126]. Mesenchymal stem cells express EMT markers, proliferate at a 
slower rate when compared to their epithelial counterparts, and are resistant to the 
majority of current cancer treatments [127-129]. Although tumor initiating 
capabilities may be a process independent of EMT [127], all three of those 
characteristics were observed in our IFF responsive cells. In HER2 positive cells, 
EMT is sometimes followed by a loss of HER2 overexpression [121] which may 
explain the spontaneous desensitization to HER2 targeted therapies. This 
phenomenon was observed in one of our HER2 positive cell lines which developed 
IFF-induced drug resistance (data not shown). Furthermore, the PI3K pathway 
typically regulates drug resistant cancer cell survival [130] specifically through 
PTEN, a PI3K inhibitor. We previously demonstrated that IFF induces strong PI3K 
phosphorylation (see Chapters 2, 4 and 5). It is possible that the combination of IFF-
induced PI3K phosphorylation and IFF-dependent EMT induction together modulate 
cellular response to HER2 therapy specifically and cancer therapies in general. 
Longer exposure to IFF is represented in this study as a series of three 
separate 24 hours IFF exposures. Although this is a longer time point than what is 
used in the majority of IFF studies, it is still very different when compared to in vivo 
system where IFF is always present. In addition, there may be a host of IFF 
consequences that are not captured in a 24 hours experiment. Future studies will focus 
on identifying the effects of continuous exposure to IFF in a 3D microenvironment. 
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This will better mimic patient tissue and allow us to identify those long term effects 
of IFF that are more relevant in vivo. 
The fact that IFF alone is able to induce EMT by affecting the levels of key 
proteins like E-cadherin, collagen type IV and vimentin in cells along with altering 
drug response suggests its role as a major contributor to breast cancer progression and 
its involvement on patient therapy response. 
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CHAPTER 4: Epithelial-to-mesenchymal transition alters 
interstitial fluid flow-induced signaling in ERBB2-positive 
breast cancer cells 
4.1 Introduction 
 Breast cancer is the most commonly reported form of cancer in women 
worldwide and is responsible for 13.7% of cancer related deaths in women [131]. The 
mortality rates associated with this and most other solid cancers is a consequence of 
cancer cell invasion into the surrounding stroma and metastasis to distant organs. 
Although many factors responsible for invasion and metastasis are still unknown, the 
influence of the breast tumor microenvironment, which consists of stromal cells, 
extracellular matrix, and soluble factors, on cancer progression is well established 
[10, 132].  
 While their importance in cancer progression has only been realized relatively 
recently, various biophysical factors are significantly altered in the tumor 
microenvironment. Changes in matrix density [63], stiffness [133], organization [61], 
interstitial fluid pressure [134], and flow [62] are all biophysical consequences of 
tumor growth that affect gene expression, proliferation, differentiation and invasion. 
Interstitial fluid flow (IFF), the movement of fluid through the tissue matrix, is 
elevated in tumors compared to normal tissue [91]. This elevated IFF is driven by 
steep fluid pressure gradients at the tumor margin [70]. Measured levels of IFF range 
from 0.1 to 1 µm s-1 in normal tissue, and 0.1 to 55 µm s-1 in tumor tissue [65-67]. 
Increased IFF is directly linked to lymph node metastasis in human cervical 
carcinoma, and increased cell motility and invasion in vitro in breast cancer, glioma, 
melanoma, and renal carcinoma cells [67, 75, 76, 79, 86]. Although increased IFF 
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appears to drive cancer cell invasion, the underlying mechanisms of interstitial fluid 
flow mechanotransduction are not fully understood. 
 To date, different studies have proposed mechanisms to explain the strong 
tumor and stromal cell migration induced by elevated IFF, although most have 
focused on highly invasive cells. In fibroblasts, IFF induced myofibroblast 
differentiation and secretion of matrix metalloproteinases (MMPs), thus indirectly 
aiding tumor cell migration through matrix remodeling [41, 86]. In metastatic cells, 
IFF altered extracellular chemokine gradients to accelerate tumor cell invasion via 
CXCR4 and CCR7-dependent chemotaxis [75, 76], and increased MMP activity via 
shear stress sensing through the glycocalyx [79]. More recently, IFF was shown to 
induce invasion against the direction of flow due to fluid drag forces and activation of 
integrins on the upstream side of the cell [77]. While we know some of its effects on 
invasive cells, the specific pathways triggered by IFF are still unclear, especially 
those that play a crucial role in the early stages of invasion. 
 At these early stages of invasion, the process of epithelial-to-mesenchymal 
transition (EMT) can play an important role.  During EMT, epithelial cells lose their 
distinctive morphology and molecular characteristics and acquire a mesenchymal 
phenotype that is often associated with invasion. This phenomenon, although 
indispensable during embryogenesis and tissue remodeling, also occurs during tumor 
development and likely plays a role in tumor progression [45]. EMT is characterized 
by the loss of epithelial baso-apical polarity and cell-cell junctions, spindle-like 
cellular morphology, and activation of transcription factors that lead to increased 
invasion [47, 48]. The induction of EMT during tumor development is a consequence 
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of external cues in the tumor microenvironment like changes in levels of cytokines 
and growth factors [48, 51]. To date, the relationship between EMT and how cancer 
cells respond to IFF has not been investigated. 
Thus, the overall goal of this study was to elucidate the molecular pathways 
activated by IFF in invasive and non-invasive breast cancer cells and determine 
whether EMT alters IFF signaling and response. Here we show for the first time that 
IFF causes an increase in tumor cell invasion via activation of phosphoinositide-3-
kinase (PI3K) in ERBB2-positive breast cancer cells. Furthermore, we demonstrate 
that pre- and post-EMT cancer cells respond to IFF via different PI3K-dependent 
pathways.  
  
4.2 Methods 
Cell Culture 
MCF10A and MCF10A-ERBB2 [135] (NeuN/NeuT) were maintained in 
DMEM/F12 supplemented with 5% donor horse serum (Atlanta Biologicals, Atlanta, 
GA), 20 ng/ml epidermal growth factor (EGF) (Peprotech, Rocky Hill, NJ), 10 µg/ml 
insulin (Sigma-Aldrich, Saint Louis, MO), 100 ng/ml cholera toxin (Enzo Life 
Sciences, Farmingdale, NY), 500 ng/ml hydrocortisone (Sigma Aldrich), and 1% 
penicillin/streptomycin (Mediatech, Herndon, VA). SKBR3, a breast cancer cell line 
that naturally expresses ERBB2, were grown in McCoy’s 5A (Mediatech) 
supplemented with 10% FBS and 1% penicillin/streptomycin. BT474 and MDA-MB-
453, other breast cancer cell lines that naturally express ERBB2, were grown in 
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DMEM (Mediatech) supplemented with 10% FBS and 1% penicillin/streptomycin. 
All cells were maintained in a humidified environment at 37oC and 5% CO2. 
 
3D Invasion Assay 
 Interstitial fluid flow was applied to cells as previously described [75, 86, 98]. 
Briefly (Fig. 15), cells were embedded in a matrix composed of 1.3 mg/ml rat tail 
tendon collagen type I (BD Biosciences, San Jose, CA) and 1 mg/ml Matrigel™ 
basement membrane matrix (BD Biosciences) at a final concentration of 5 x 105 
cells/ml inside culture inserts with 8 µm diameter pores (Millipore, Billerica, MA). 
For static (control) conditions, serum-free media levels inside and outside the insert 
were kept approximately equal, resulting in a minimal hydrostatic pressure difference 
across the gel and no measurable interstitial flow. For IFF conditions, serum-free 
media was added under the insert (100 μl) and above the gel (650 μl).  
 
 
Figure 15: Schematic of the 3-D interstitial fluid flow invasion assay. Cells (green) are embedded 
in a collagen/Matrigel matrix (pink) media is added to simulate both control (static) and flow 
conditions. 
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 The hydrostatic pressure difference generated was approximately 1 mm Hg. 
After 24 hours of either physiological interstitial flow (approximate flow velocity 
~0.1 µm/s) or static conditions, invasion was measured by counting the number of 
cells that invaded through the matrix and migrated across the porous membrane. 
Migrated cells on the underside of the culture insert membranes were fixed in 4% 
paraformaldehyde in PBS for 30 minutes and permeabilized with 0.5% Triton X-100 
in PBS for 10 minutes. Cells were then stained with Alexa Fluor 488-conjugated 
phalloidin (6 U/ml) (Life Technologies) and 4′,6-diamidino-2-phenylindole (DAPI) 
(2 µg/ml) (MP Biomedicals, Santa Ana, CA). Labeled cells were visualized on an 
epifluorescence microscope (Leica Microsystems). DAPI-stained nuclei at five 
randomly selected locations of each membrane were counted. F-actin staining was 
used to confirm that positive DAPI stain corresponded to cells. Percent invasion was 
calculated with the following equation: 
 
 llsSeededNumberofCeimageArea
rfaceAreaMembraneSulCountAverageCel
Invasion
*
**100
%   
 In some instances, percent invasion was normalized to the static control 
condition to allow for comparison between independent experiments. To determine 
the functional role of specific proteins, pharmacological inhibitors were used to block 
specific signaling proteins (see Table 1 for a list of inhibitors and corresponding 
concentrations presented in this study). When used, inhibitors were added to the 
collagen matrix and experimental medium at the appropriate concentrations. 
Experiments were repeated at least twice with a minimum sample size of n = 3 for 
each experiment (total minimum sample size n = 6). 
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Table 1: List of inhibitors, their targets, and concentrations used 
Name Protein target Concentration (µM) 
LY294002 PI3K 10, 50 
PIK75 p110α 0.01 
TGX221 p110β 0.1 
AMD3100 CXCR4 12.6 
WZ811 CXCR4 0.1 
Pertussis toxin Gαi 0.1 
 
 
TGF-β1 treatment 
   EMT was induced in NeuN cells via treatment with recombinant human TGF-
β1 (Peprotech). An optimal concentration of TGF-β1 was first determined by treating 
NeuN cells at varying concentrations of TGF-β1 (3, 5, 10, 20 and 50 ng/ml) for 6 
days. A concentration of 20 ng/ml was found to most effectively induce EMT (low E-
cadherin expression, high vimentin expression, elongated morphology). NeuN cells 
were treated with this concentration in full media for 6 days, with a media change 
after 3 days. 
 
Western Blot 
Following the 3D invasion assay, total and phospho-protein levels were 
determined by western blot. Cells were isolated from the matrix using 2.5 mg/ml 
collagenase D (Roche, Indianapolis, IN) for 30 minutes. The resulting solution was 
centrifuged, and the pellet was washed with PBS and resuspended in RIPA lysis 
buffer (150 mM NaCl, 1% NP40, 0.5% DOC, 50 mM Tris-HCl at pH 8, 0.1% SDS, 
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10% glycerol, 5 mM EDTA, 20 mM NaF and 1 mM Na3VO4). Lysates were cleared 
via centrifugation at 16,000 x g for 20 minutes at 4°C. Antibodies used were: rabbit 
polyclonal anti-phospho PI3K and total PI3K (1:500, Cell Signaling, Danvers, MA), 
rabbit polyclonal anti-β-actin (1:3,000, Cell Signaling), rabbit monoclonal anti-
vimentin (1:1,000, Abcam), rabbit monoclonal anti-E-cadherin (1:1,000, Abcam), 
rabbit polyclonal anti-phospho and total CXCR4 (1:500, Abcam), rabbit polyclonal 
anti-p110α and β (1:1,000, Cell Signaling), and goat anti-rabbit HRP (1:10,000, 
Abcam). 
 
Immunofluorescence 
For visualization of EMT markers, cells were plated onto 8 well chamber 
slides at 10,000 cells per well. After 16 hours, cells were fixed in 4% 
paraformaldehyde in PBS for 30 minutes and permeabilized with 0.5% Triton X-100 
in PBS for 10 minutes. This was followed by 1 hour in blocking solution (1% BSA, 
0.1% goat serum). Cells were stained with rabbit monoclonal anti-vimentin (1:100) 
(Abcam) for 16 hours, then washed in PBS 3 times. Alexa Fluor 488-conjugated 
phalloidin (6 U/ml), DAPI (2 ug/ml), and Alexa Fluor 555 conjugated anti-rabbit IgG 
was incubated on the cells for 16 hours then washed in PBS 3 times. Fluorescence 
was visualized on an epifluorescence microscope (Leica Microsystems). 
 
Microarray and Quantitative RT-PCR  
Changes in gene expression in NeuN and NeuT cells were identified by 
microarray analysis. Total RNA was extracted from cells embedded in 3-D gels (6 
  
52 
 
biological replicates per sample) using RNeasy mini Kit (Qiagen, Germantown, MD). 
RNA was submitted to the Wistar Institute genomics core facility for amplification. 
Epicentre TargetAmp™ Nano Labeling Kit for Illumina® Expression BeadChip was 
used at 100 ng RNA and hybridized on an Illumina HT12v4 chip. Data were analyzed 
with PARTEK Genomics Suite and Database for Annotation, Visualization and 
Integrated Discovery (DAVID) online tools.  
 Quantitative RT-PCR (qRT-PCR) was performed on cDNA reversed 
transcribed using QuantiTech Reverse Transcription kit and QuantiTech SYBR Green 
PCR kit (Qiagen). Primers for human interleukin 6, desmoplakin, and integrin subunit 
α6 (Quantitech, Qiagen) were used to validate the microarray analysis and quantify 
mRNA expression differences. 
 
Data and Statistical Analysis  
Data are expressed as mean ± standard error of the mean. Differences among 
conditions were tested using Student’s t-tests (for two groups) or two-way analysis of 
variance (ANOVA) (for three or more groups) using GraphPad Prism. When 
ANOVA identified a significant difference, a Bonferroni post-test was employed for 
multiple comparisons. Differences were accepted as significant at p < 0.05. 
 
4.3 Results 
Interstitial fluid flow induces invasion of breast cancer cells through PI3K activation 
To model non-invasive and invasive cells, we used a previously developed 
model of breast cancer based on MCF10A human mammary epithelial cells 
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engineered to overexpress ERBB2 [135]: MCF10A cells retrovirally transduced with 
either wild-type ERBB2 (NeuN) or a constitutively active mutant of ERBB2 (NeuT). 
When cultured in 3D conditions, NeuN cells exhibit behavior of pre-invasive ERBB2 
positive ductal carcinoma in situ (DCIS) [135], while NeuT cells behave like ERBB2 
positive invasive ductal carcinoma (IDC) [136]. Using a 3D invasion assay where 
single cells are embedded in stroma-like matrix, we measured invasion by counting 
the number of transmigrated cells (Fig. 15). We observed a 2-fold increase in 
invasion in response to 0.1 µm s-1 IFF in both NeuN and NeuT cells (Fig. 16A).  
 
 
Figure 16: IFF-induced invasion occurs through p85 activation. A) IFF increases invasion of 
NeuN and NeuT. Percent invaded cells after 24 hours in 3-D IFF assay. All values are mean ± 
SEM. Student t test (*: p < 0.05; **: p < 0.01, ***: p < 0.001), n>12. B) IFF induces activation of 
PI3K in NeuN and NeuT. Representative western blot of phosphorylation of PI3K regulatory 
subunit (p85) after 24 hours of static or flow conditions in 3D flow invasion assay; β actin was 
used as loading control. C) PI3K activity is necessary for IFF-induced invasion in both cell lines. 
IFF-induced invasion is decreased in the presence of 10 µM LY294002, a pan PI3K inhibitor. All 
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values are mean ± SEM. Student t test and 2-way ANOVA (*: p < 0.05; **: p < 0.01, ***: p < 
0.001), n>6. 
 
 
To determine the signaling pathways involved in the observed IFF-induced 
invasion, we examined pathways known to be important in invasion of HER2 positive 
breast cancer cells (HER2, MAPK, PI3K). We isolated cells from gels after the 3-D 
invasion assay and harvested protein from the resulting cells. Western blot revealed 
an increase in phosphorylated p85 (the regulatory subunit of class I PI3Ks) in both 
NeuN and NeuT cells treated with IFF (Fig. 16B). To confirm that our results were 
not specific to the engineered MCF10A cell lines, treatment with IFF of other breast 
cancer cells overexpressing ERBB2 including SKBR3, BT474, and MDA-MB-453 
also induced increased invasion coupled with increased PI3K phosphorylation 
compared to static conditions (Fig. 17 A-C).  
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Figure 17: IFF induced invasion through PI3K is also observed in other HER2 positive cell lines. 
IFF induces invasion of SKBR3 (A), BT474 (B), MDA-MB-453 (C) coupled with PI3K activation. 
Percent invaded cells after 24 hours in 3-D IFF assay and representative western blot of 
phosphorylation of PI3K. D) SKBR3 and MDA-MB-453 show decreased IFF-induced invasion in 
the presence of 50 uM LY294002, a pan PI3K inhibitor. All values are mean ± SEM. Student t 
test and 2-way ANOVA (*: p < 0.05; **: p < 0.01, ***: p < 0.001), 15>n>6. 
 
 
To test whether PI3K activity was required for IFF-induced invasion we 
treated cells with the PI3K inhibitor LY294002 (a pan-PI3K inhibitor). Treatment 
with LY294002 decreased IFF-induced invasion in NeuN, NeuT (Fig. 16D) and 
breast cancer cells SKBR3 and MDA-MB-453 (Fig. 17D). These data suggest that 
IFF increases invasion in ERBB2 overexpressing breast cancer cells via activation 
and subsequent downstream signaling through PI3K.   
 
p110β modulates response to interstitial fluid flow in NeuT but not NeuN cells 
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       Class I PI3Ks are present in cells as heterodimers composed of a regulatory 
(typically p85 or p55) and catalytic subunit (p110) [137]. The p110 catalytic subunit 
is responsible for propagating downstream signaling through its kinase activity [138]. 
Using inhibitors that specifically target the β (TGX-221) or α (PIK-75) p110 catalytic 
subunit of PI3K, we observed that in NeuN cells, only the p110 inhibitor blocked 
IFF-mediated invasion (Fig. 18A). However in NeuT cells, inhibiting both p110α and 
p110β decreased IFF-induced invasion (Fig. 18B). NeuN and NeuT cells expressed 
similar protein levels of p110α and p110β (Fig. 18C), thus ruling out altered levels of 
these isoforms as the reason for this difference.  
 
 
Figure 18: Different p110 isoforms are necessary for IFF induced invasion in NeuN and NeuT. 
A-B) Both p110α and p110β are necessary for flow response in NeuT only. Cellular response to 
P110 isoforms specific inhibitors PIK75 and TGX221 (p110α and p110β inhibitors respectively) 
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in NeuN (A) and NeuT (B). All values are mean ± SEM. Student t test (*: p < 0.05. *: p < 0.05; 
**: p < 0.01, ***: p < 0.001), n=6. C) Both cells express similar levels of p110 isoforms. 
Representative western blot of p110α and β in NeuN and NeuT; β actin was used as loading 
control. 
 
 
 
CXCR4 regulates PI3K activity in response to interstitial fluid flow in NeuT cells 
Since previous studies have linked p110α to receptor tyrosine kinase signaling 
and p110β to G protein coupled receptors (GPCRs) [139-141], we investigated the 
role of chemokine receptors (a family of GPCRs) in the IFF-induced invasion of 
NeuT cells. CXCR4 is a known modulator of breast cancer invasion [142, 143] and 
IFF-induced glioma cell invasion was previously shown to be dependent on CXCR4 
[76]. Treating NeuT cells with antagonists of the chemokine receptor CXCR4 
(AMD3100 or WZ811) significantly reduced IFF-induced invasion (Fig. 19A). In 
contrast, AMD3100 and pertussis toxin (Gαi subunit inhibitor of all GPCRs [144, 
145]) had no effect on IFF-mediated invasion of NeuN cells (Fig. 19B), suggesting 
that chemokine receptors, including CXCR4, are not involved in the molecular 
pathway activated by IFF in NeuN cells. CXCR4 inhibitors also had no effect on IFF-
mediated invasion in the non-invasive HER2 positive cell line SKBR3 (data not 
shown).  
To test whether CXCR4 signaling was associated with PI3K activation, we 
examined the effects of treating NeuT or NeuN cells with AMD3100 on p85 
phosphorylation during IFF-mediated invasion. IFF-induced PI3K phosphorylation 
was decreased in NeuTs when the cells were treated with AMD3100 but 
phosphorylation was only weakly inhibited in NeuN (Fig. 19C). Interestingly, 
CXCR4 protein levels were similar in NeuN and NeuT cells (Fig. 20).  
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Figure 19: CXCR4 activity is required for IFF-induced invasion in NeuT but not NeuN. A) 
Changes in invasion in the presence or absence of CXCR4 inhibitors (AMD3100 and WZ811) in 
NeuT. B) AMD3100 and pertussis toxin are not necessary for IFF-induced invasion in NeuN. C) 
AMD3100 inhibits IFF-induced PI3K activation in NeuT but not in NeuN. Representative 
western blot of phospho-p85 after 24 hours in 3D invasion assay with and without the inhibitor 
in NeuN and NeuT; β actin was used as loading control. D) Changes to flow induced invasion 
when exogenous CXCL12 is added to surrounding matrix and media. NeuT respond to fluid flow 
only in the presence of a CXCL12 gradient. All values are mean ± SEM. Student t test (*: p < 
0.05. *: p < 0.05; **: p < 0.01, ***: p < 0.001); n≥6. 
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Figure 20: NeuN and NeuT express similar levels of CXCR4 and IFF does not alter CXCR4 total 
and phosphorylated protein levels. Representative western blot of total CXCR4, phosphorylated 
CXCR4 with loading control actin. 
 
 
 
CXCR4 and its ligand CXCL12 have been previously implicated in IFF-
mediated glioma invasion by autologous chemotaxis [76]. In autologous chemotaxis, 
a transcellular gradient is generated by the combination of autocrine chemokine 
secretion and interstitial flow [87].  To determine if a CXCL12 gradient was 
necessary for IFF-induced invasion of NeuT cells, exogenous CXCL12 was added to 
the surrounding media and matrix at a uniform concentration of 80 ng/ml (10nM). At 
this concentration, the cells’ CXCR4 receptors should be approaching saturation (KD 
~14 nM) [146], effectively blocking gradient sensing. Under these conditions NeuT 
cells no longer responded to IFF (CXCL12 condition) compared to a 2-fold increase 
in invasion in the control flow condition (Fig. 19D). These data suggest that NeuT 
cells, unlike NeuN cells, require a gradient of CXCL12 for IFF-induced activation of 
PI3K and invasion, consistent with chemokine-dependent autologous chemotaxis. 
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TGF-β1-induced EMT alters the mechanism of interstitial flow-induced invasion in 
NeuN cells 
Having identified separate IFF-induced pathways in NeuN and NeuT cells, 
our next goal was to determine some of the fundamental differences between these 
cells responsible for the observed differences in IFF-induced invasion. NeuN cells 
adopted more epithelial-like shapes on 2D cell culture plates and invaded in clumps 
of cells similar to their parental MCF10A counterparts (Fig. 21). However NeuT 
invaded as single cells and were characterized by a spindle-like morphology.  
 
 
 
Figure 21: NeuN invade in clumps similar to the non-tumorigenic epithelial cell line MCF10A. 
NeuT however invade as single cells. Invaded cells were stained directly on membranes with 
DAPI (blue) and Phalloidin (green). White bars represent 50 µm. 
 
 
 
Thus, we hypothesized that NeuT cells may have undergone EMT and this 
may explain the difference in IFF response. We probed for protein expression of 
epithelial and mesenchymal markers, and observed loss of E-cadherin and increased 
levels of vimentin in NeuT cells when compared to NeuN cells (Fig. 22 A, B). Both 
of these proteins are known markers of EMT [49].  
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Figure 22: NeuT cells have undergone EMT similar to TGF-β1 dependent EMT induction in 
NeuN. A) Compared to NeuN, NeuT cells express lower levels of epithelial markers. 
Representative western blot of E-cadherin; β actin was used as loading control. B) Compared to 
NeuN, NeuT cells express higher levels of mesenchymal markers. Representative immuno-
fluorescence of vimentin from cells plated on collagen I coated cover-slip. C) Compared to 
control, NeuNEMT cells express lower levels of epithelial markers. Representative western blot 
of E-cadherin; β actin was used as loading control. D) Compared to control, NeuNEMT cells 
express higher levels of vimentin. Representative immuno-fluorescence of vimentin from cells 
attached to the underside of membrane after IFF invasion assay. White bars represent 50 µm. 
 
 
 
To examine gene differences between NeuN and NeuT cells further, we 
profiled gene expression using microarray analysis. Table 2 lists a number of known 
EMT-associated genes that were significantly different when comparing NeuT and 
NeuN mRNA expression (log2 transformed fold change is represented). The 
expressions of all these genes agree with published EMT-associated data [147-149].  
 
Table 2: List of EMT genes differentially expressed between NeuT and NeuN  
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The genes below are published EMT genes whose expression profile agrees with our dataset. They 
were identified in our microarray data set with a significant log2 transformed expression ratio 
(NeuT/NeuN) of at least ± 1.4 
 
EMT UP-REGULATED GENES 
Gene Symbol (name) NeuT/NeuN P value 
CDH2 (N-cadherin) +2.7 6.8x10-8 
GNG11 (guanine nucleotide-binding protein) +2.9 7.2x10-11 
IGFBP4 (insulin-like growth factor-binding protein 4) +1.9 1.2x10-7 
STEAP1 (metalloreductase STEAP1) +3.4 1.1x10-9 
VCAN (versican) +1.5 1.6x10-8 
WNT5A (Protein Wnt-5a) +1.6 2.0x10-8 
EMT DOWN-REGULATED GENES 
Gene Symbol (name) NeuT/NeuN P value 
PPPDE2 (Desumoylating isopeptidase 1) -1.4 4.0x10-7 
CDH1 (E-cadherin) -5.4 8.4x10-9 
 
 
We validated the microarray result with quantitative RT-PCR of three of the 
identified genes (Fig. 23). These results supported the hypothesis that NeuT cells 
display a more mesenchymal-like phenotype when compared to NeuN cells. 
 
  
63 
 
 
Figure 23: Validation of microarray data using quantitative RT-PCR. Interleukin 6 (IL6) 
expression is higher in NeuT. Desmoplakin (DSP) and integrin alpha 6 (ITGA6) expression is 
lower in NeuT. 
 
 
 
To determine whether EMT contributes to the altered IFF response, EMT was 
induced in NeuN cells using the known EMT inducing growth factor TGF-β1 [48, 
150]. The cells were treated for 6 days with 20 ng/ml TGF-β1 and EMT induction 
was confirmed using western blot and immunofluorescence. NeuNEMT cells show 
lower levels of E-cadherin and higher levels of vimentin when compared to their 
control NeuN counterparts (Fig. 22C, D). As expected, the NeuN cells induced to 
undergo EMT had higher levels of basal invasion (Fig. 24B). However, in line with 
our previous findings in NeuT cells, we observe that IFF-induced invasion in 
NeuNEMT cells was inhibited by both pertussis toxin and CXCR4 (Fig. 24A-B). In 
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addition, IFF-induced PI3K phosphorylation in the presence of AMD3100 was 
significantly reduced (Fig. 24C) in NeuNEMT cells, similar to NeuT cells (Fig. 19C). 
Consistent with this result, treatment of NeuNEMT cells with p110β inhibitor 
(TGX221) reduced IFF-mediated invasion, in contrast to their untreated NeuN 
counterparts (Fig. 24D), but similar to NeuT cells (Fig. 18B). Thus, these data support 
the hypothesis that ERBB2 expressing breast cancer cells that have undergone EMT 
invade in response to IFF through a CXCR4- and p110-dependent mechanism.  
 
 
Figure 24: TGFβ1-induced EMT in NeuN leads to CXCR4- and p110β-dependent IFF-induced 
invasion. A) Changes in invasion in the presence or absence of pertussis toxin. Inhibiting GPCR 
activity in NeuNEMT blocks IFF-induced invasion but not in control NeuN. B) Changes in 
invasion in the presence or absence of CXCR4 inhibitors, AMD3100. Inhibiting CXCR4 activity 
in NeuNEMT blocks IFF-induced invasion but not in control NeuN. C) AMD3100 decreases IFF-
induced PI3K activation in NeuNEMT but not in control. Representative western blot of phospho-
p85 after 24 hours in 3D invasion assay with and without the inhibitor; β actin was used as 
loading control. D) Changes in invasion in the presence or absence of p110β inhibitors, TGX221. 
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Inhibiting CXCR4 activity in NeuNEMT blocks IFF-induced invasion but not in control NeuN.  
All values are mean ± SEM. Student t test (*: p < 0.05. *: p < 0.05; **: p < 0.01, ***: p < 0.001); 
n≥6. 
 
 
4.4 Discussion  
In the present study, we examined the role of key intracellular signaling 
pathways that mediate interstitial fluid flow-induced invasion in ERBB2-expressing 
breast cancer cells. In all breast cancer cells tested, we found that IFF induced 
activation of PI3K as measured by p85 phosphorylation. In addition, these breast 
cancer cells require PI3K activity for IFF-mediated invasion as inhibition of PI3K and 
the p110α catalytic subunit blocked IFF-mediated invasion. However, cells that have 
undergone EMT (NeuT and NeuNEMT cells) require additional signals, including 
activation of chemokine receptors. Indeed, we showed that inhibitors of CXCR4 and 
p110, a p110 isoform that is GPCR-regulated [139-141], specifically blocked IFF-
mediated invasion in breast cancer cells that have undergone EMT. Our data suggest 
a model where, as cells undergo EMT, the signaling pathways activated by interstitial 
fluid flow to induce invasion change significantly (Fig. 25). 
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Figure 25: Proposed mechanism of interstitial fluid flow in ERBB2 positive breast cancer. 
Separate signaling pathways are activated in response to IFF in our cell model but they all 
converge at class I PI3K. In pre-invasive cells (NeuN) IFF activates PI3K through an unknown 
receptor leading to increased invasion via the p110α catalytic subunit. In invasive cells similar to 
those that have undergone EMT (NeuT, NeuNEMT), IFF activates PI3K through CXCR4 which 
leads to increased invasion via both p110 catalytic subunits. This occurs because the combination 
of autocrine CXCL12 secretion and IFF creates a chemokine gradient around the cells, driving 
chemoinvasion in the direction of IFF via autologous chemotaxis [75]. 
 
 
The PI3K pathway plays a central role in numerous cellular processes crucial 
for cancer progression. This pathway has been implicated in invasion, proliferation, 
transformation and cell survival [151, 152]. Mutations or alterations of this pathway 
are the most frequent in all human cancers, making it an important target of cancer 
therapeutics [151]. This work supports the importance of targeting the PI3K pathway 
in order to curtail breast cancer invasion, especially in those with prominent IFF. 
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PI3K is present in cells as a heterodimer complex made up of a regulatory and 
catalytic subunit. Cancer specific mutations have been observed in the four catalytic 
p110 isoforms (α, β, δ, γ) of the class I kinase [152]. IFF led to phosphorylation of 
p85 in all cells tested, suggesting that class I PI3K is central to signals activated by 
IFF. However, as cancer cells underwent EMT, we found changes in p110 subunit 
dependency. Only breast cancer cells expressing a mesenchymal phenotype 
(determined by E-cadherin and vimentin expression) required p110activity. As 
mentioned above, p110α has been linked to downstream activity of receptor tyrosine 
kinases, while p110β has been linked to G protein coupled receptors [139-141]. This 
is consistent with our data that EMT cells required the GPCR and chemokine receptor 
CXCR4 for IFF-induced invasion. Our findings suggest that breast cancer cells 
undergoing EMT require both PI3K catalytic subunits p110α and p110β for IFF-
mediated invasion and that this pathway may be targeted for blocking invasion of 
aggressive breast cancers. We show that by specifically blocking either p110α or 
p110β, we can decrease IFF-induced invasion in EMT-like cells.  Our findings 
suggest that drugs targeting p110 isoforms may be used to block invasion of 
aggressive breast cancers and that may have less toxic compared to using pan-PI3K 
inhibitors.   
We demonstrated that IFF-induced PI3K activation occurs through separate 
upstream receptors, leading to downstream signaling in a p110 isoform-specific 
fashion (Fig. 25). IFF-specific activation of PI3K in cells that have undergone EMT 
(NeuT and NeuNEMT) occurs via CXCR4. CXCR4 is a known prognosis marker for 
breast cancer metastasis [142] and had been implicated in breast cancer invasion 
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[153]. The role CXCR4 plays in IFF-induced glioma invasion was previously 
described as a result of autologous chemotaxis through its ligand CXCL12 [76]. Here, 
as the cells secrete CXCL12, IFF creates a CXCL12 gradient around the cells in the 
direction of flow, leading to a higher chemokine concentration on the downstream 
side of the cells. We did not observe an increase in total or phosphorylated CXCR4 
due to IFF. This suggests that IFF does not alter the levels of these proteins but may 
alter how the cells migrate by creating a small but biologically relevant transcellular 
gradient [87]. The fact that this phenomenon is only observed in cells that have 
undergone EMT suggests that in addition to inducing invasion in pre-invasive cells, 
IFF may play a role in sustaining invasion as cells move through the stroma 
individually. Invasive cells, like those which have undergone EMT, have been shown 
to be more sensitive to chemokine gradients [154, 155]. This may allow them to home 
to specific organs producing a chemoattractant [156, 157], but it may also facilitate 
IFF-induced invasion, as we have outlined here. Although basal invasion levels 
between NeuN and NeuT are similar, the mechanism by which these cells invade 
appears to be different. NeuN cells have a tendency to invade collectively while NeuT 
invade as single cells (Fig. 21). We further profiled mRNA and protein of these cells 
and observed that NeuT lacked key epithelial cell-associated proteins/genes (E-
cadherin, integrin α6) and expressed higher levels of mesenchymal markers (N-
cadherin, vimentin) suggesting that EMT alters the mode of invasion of cells, and this 
leads to changes in the response of cells to IFF. To test this idea specifically, we 
showed that induction of EMT in NeuN converted the IFF invasion response from 
chemokine-independent to chemokine receptor-dependent.  
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Although our data suggest potential relevance of our findings to treatment of 
HER2 positive DCIS, the study focuses on invasion of single cells embedded in a 
matrix. DCIS cells in vivo are organized in 3-dimensional complex structures that are 
highly dependent on cell-to-cell interactions and basement membrane restrictions 
[18]. Their invasion outside the stroma is also dependent on stroma-associated cells, 
which are well known to have both positive and negative influences on cancer 
progression [10]. In the future, investigating the role of IFF on 3-dimensional DCIS 
structures in a more clinically relevant matrix will lead to better understanding of the 
role of IFF on breast cancer invasion. In addition, questioning the role of known 
mechanotransducers by targeting proteins such as integrins and glycoccalyx, which 
have both been implicated in IFF-induced response [77, 79], may help identify the 
upstream mediator of PI3K phosphorylation in NeuN cells. Further studies should 
also focus on identifying the implications of EMT in altering IFF response in other 
cancers (e.g. melanoma, glioma and renal cell carcinoma).  
Taken together, our results demonstrate for the first time that interstitial fluid 
flow increases invasion of cells via separate mechanisms depending on the stage of 
the cancer cells. This is the first study to examine the effect of IFF on separate stages 
of breast cancer, especially in the context of how it may influence the early steps of 
tumor progression. We showed that IFF increases the invasion of different types of 
human mammary breast cancer cells through activation of PI3K. We further 
demonstrated that EMT alters how cells respond to IFF, engaging a 
CXCR4/CXCL12-dependent autologous chemotaxis mechanism that signals through 
p110β. Understanding these cellular responses to interstitial fluid flow will increase 
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our understanding of how biophysical forces interact with molecular factors to drive 
breast cancer progression and may help identify novel therapeutic regimens. 
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CHAPTER 5: Interstitial fluid flow induces invasion of non-
invasive breast cancer spheroids 
5.1 Introduction 
Ductal carcinoma in situ (DCIS) is a pre-invasive stage of breast cancer where 
the cells, although abnormal in their proliferation and gene expression profile, are 
non-invasive. They remain within the confined structures of the mammary duct 
enclosed by the basement membrane. In response to still unknown triggers, these cells 
develop the ability to invade beyond the basement membrane and infiltrated the 
surrounding stroma. The resulting cancer stage is known as invasive ductal carcinoma 
(IDC). Unfortunately, factors regulating the invasive and metastatic behavior of 
cancer cells are complex and much remains unknown [8].  
Breast cancer-associated mortality is primarily the result of IDC, where cells 
are able detach from the primary tumor and metastasize to distant tissues and organs 
such as the lymph nodes, bone marrow, liver, lungs, and brain [158, 159]. The 5-year 
survival rate of breast cancer falls from 98% for localized tumors to 23% for 
metastatic disease [4].  These collective findings underscore the importance of 
identifying both the molecular and biophysical factors that put patients at risk of 
invasion and metastasis, which will allow for the development of better diagnostics 
and treatments. Improving both disease survival and clinical management of patients 
will require understanding of the molecular mechanisms that regulate this transition 
and the identification of key factors at play. 
In breast cancer, it is well established that genetic dysregulations, coupled 
with changes in the tumor microenvironment, play key roles in the transition from 
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ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) [10, 32, 33, 60, 
160]. ERBB2 is an oncogene that encodes for the receptor tyrosine kinase HER2, a 
protein known to increase the aggressiveness of breast cancer [93]. Poor breast cancer 
prognosis including metastasis has been correlated with the overexpression of HER2 
in 15-30% [94, 95] of all human breast cancers. Additionally, not only is HER2 
overexpressed in more than 50% of DCIS cells, but the risk of developing IDC from 
DCIS is six times higher when cells overexpress HER2 [24]. Approximately 30% of 
patients who are diagnosed with DCIS will develop invasive breast cancer despite 
therapy [18, 93]. This increased invasion occurs via activation of members of the 
mitogen activated protein kinase (MAPK) and phosphoinositide-3 kinase (PI3K) 
pathways [25, 26]. For this reason, many patients diagnosed with localized tumors are 
over-treated with harsh therapies even though the majority of these tumors never 
become lethal. The most common treatment for DCIS is lumpectomy followed by 
radiation therapy. Additional treatments include mastectomy and hormonal therapy 
and these are usually followed by numerous physical and emotional side effects. 
We previously showed in chapters 2, 3, and 4 that interstitial fluid flow (IFF), 
the movement of fluids within the interstitial space, induces the invasion of normal 
and pre-invasive cells in 3D through a PI3K-dependent pathway. In our previous 
experiments along with experiments performed in other groups [75, 76, 86], the 
invasion of single cells embedded in a stroma-like matrix was measured. These single 
cell experiments help elucidate the intricate signaling mechanism employed by IFF in 
clinical systems where the cells are invading as individual entities such as in 
metastasis. They however are not relevant in identifying the role of IFF in the 
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individual cellular detachment from the primary tumor that is required in the initial 
steps of invasion. The effect IFF has on the early steps of tumor invasion of DCIS-
like acini or spheroids has never been studied. In the current study, we aimed to 
identify the role IFF plays in initiating invasion by otherwise non-invasive 3-D 
normal and DCIS-like spheroid structures. 
 
5.2 Methods 
Cell Culture 
To model normal breast epithelium, DCIS and IDC, we used a previously 
developed model of breast cancer based on MCF-10A human mammary epithelial 
cells engineered to overexpress HER2 [96, 97]: MCF-10A human mammary 
epithelial cells, MCF-10As retrovirally transduced with wild-type ERBB2 (NeuN) and 
MCF10A overexpressing a constitutively active mutant of ERBB2 (NeuT). These 
cells were maintained in DMEM/F12 supplemented with 5% donor horse serum 
(Atlanta Biologicals, Atlanta, GA), 20 ng/ml epidermal growth factor (EGF) 
(Peprotech, Rocky Hill, NJ), 10 µg/ml insulin (Sigma-Aldrich, Saint Louis, MO), 100 
ng/ml cholera toxin (Enzo Life Sciences, Farmingdale, NY), 500 ng/ml 
hydrocortisone (Sigma Aldrich), and 1% penicillin/streptomycin (Mediatech, 
Herndon, VA). Cell lines naturally expressing HER2 were also used: BT474, MDA-
MB-453 and SKBR3. BT-474 and MDA-MD-453 cells (ATCC, Manassas, VA) were 
grown in DMEM (Mediatech) supplemented with 10% fetal bovine serum (FBS) 
(Atlanta Biologicals) and 1% penicillin/streptomycin. SKBR3 cells were grown in 
McCoy’s 5A (Mediatech) supplemented with 10% FBS and 1% 
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penicillin/streptomycin. All cells were maintained in a humidified environment at 
37oC and 5% CO2. 
 
3D Acini Invasion Assay  
MCF10A, NeuN and NeuT cells were grown in acini following a protocol 
adapted from [161] and then subjected to interstitial fluid flow. Briefly, 24-well cell 
culture plates were coated with 100 µl growth-factor-reduced Matrigel. Cells were 
resuspended in 3D medium (DMEM/F12, 2% donor horse serum, 10 ug/ml insulin, 
100 ng/ml cholera toxin, 500 ng/ml hydrocortisone, 1% penicillin-streptomycin, 5 
ng/ml EGF) containing 2% growth-factor-reduced Matrigel and plated at a 
concentration of 5,000 cells/ml. After 12 days, acini were dislodged by gentle 
pipetting and seeded in 1.3mg/ml collagen gels inside 8 µm diameter pore cell culture 
inserts.  Spheroids were then exposed to flow and static conditions for 48 hours. For 
static (control) conditions, serum-free media levels inside and outside the insert were 
kept approximately equal, resulting in a minimal hydrostatic pressure difference 
across the gel and no measurable interstitial flow. For IFF conditions, serum-free 
media was added under the insert (100 μl) and above the gel (650 μl). Every 4-6 
hours, media was replenished above the gels of the flow transwells using flow-
through media.  
 
Immunofluorescence Microscopy 
Gels were fixed and stained with Alexa Fluor 488-conjugated phalloidin 
(1:50), DAPI (1:500), and either mouse monoclonal anti-laminin V (1:100) or rabbit 
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monoclonal anti-collagen IV antibody (1:100) (Abcam, Cambridge, MA) to visualize 
the basement membrane. 
 Fluorescent images were analyzed using MATLAB and its Image Processing 
Toolbox. Pictures were reduced into binary images using the Otsu algorithm and the 
background pixels were removed in order to de-noise the image. In order to separate 
individual spheroids and define their outline, the area of each staining was calculated 
using the regionprops MATLAB function. Collagen IV fluorescent intensity was 
normalized to total F-actin intensity to obtain loss of collagen IV levels. The total 
number of protrusions per spheroid was counted manually.  Two additional counters 
(each blinded) were used to double check counter bias. 
 
Western Blotting 
Following the invasion assay, total and phospho-protein levels were 
determined by western blot. Spheroids were isolated using 2.5 mg/ml collagenase D 
(Roche, Indianapolis, IN) for 30 minutes. The resulting solution was centrifuged, and 
the pellet was washed with PBS and resuspended in RIPA lysis buffer (150 mM 
NaCl, 1% NP40, 0.5% DOC, 50 mM Tris-HCl at pH 8, 0.1% SDS, 10% glycerol, 5 
mM EDTA, 20 mM NaF and 1 mM Na3VO4). Lysates were then cleared via 
centrifugation at 16,000 x g for 20 minutes at 4°C. The antibodies used were: rabbit 
polyclonal anti-phospho PI3K and total PI3K (1:500, Cell Signaling, Danvers, MA), 
rabbit polyclonal anti-β-actin (1:3000, Cell Signaling), goat anti-rabbit HRP(1:10000, 
Abcam).  
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Data and Statistical Analysis  
Data are expressed as mean ± standard error of the mean. Differences among 
treatment groups were tested using Student’s t-test (for two groups) or two-way 
analysis of variance (ANOVA) (for three or more groups) as appropriate using 
GraphPad Prism. When ANOVA identified a significant difference, a Bonferroni 
post-test was employed for multiple comparisons. Differences were accepted as 
significant at p < 0.05. 
 
5.3 Results 
Interstitial fluid flow induces loss of basement membrane of DCIS-like acini 
In this study, we used three types of cells that each represented a distinct stage 
of breast cancer progression. It was previously shown that when cultured in 3D 
condition, MC10A, NeuN and NeuT cells exhibited behavior expected of normal, 
pre-invasive-HER2 positive and invasive-HER2 positive cancer phenotypes [96, 97]. 
We cultured MCF10A, NeuN, and NeuT in a three-dimensional reconstituted 
basement membrane matrix. After 12 days, these cells formed separate types of acini 
structures (Fig. 26). MCF10A cells developed 3D spheroid structures that were 
surrounded by an intact basement membrane (positive collagen IV staining), no 
protrusions, and hollow centers (lumen). NeuN acini had lost the distinctive lumen 
but had intact basement membranes. NeuT 3D structures appeared more disorganized 
and less compact, and exhibited a discontinuous or non-existent basement membrane. 
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Figure 26: 3-D structures observed after 12 days on Matrigel. Basement membrane is 
represented as Collagen IV staining in green (top) and DAPI stained nuclei in blue. MCF10A 
and NeuN have intact basement membranes. 
 
Once formed, these 3D multicellular structures were dislodged and embedded 
in collagen type I. IFF was applied for 48 hours and the pressure gradient was 
maintained by replenishing the media on the inside of the cell culture insert using 
flowed-through media. NeuN spheroids were used to determine the effects of IFF on 
HER2 DCIS-like acini. We observed a decrease in periacinar laminin V – a basement 
membrane associated protein - in response to interstitial flow (Fig. 27). In addition, a 
few of the acini that were subjected to IFF possessed invading cells in the vicinity of 
the spheroid (see arrow in Fig. 27) suggesting these cell originated from the main 
structure but had invaded. 
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Figure 27: NeuN 12-day old acini plus 2 days under flow or static conditions; decreased laminin 
V staining in flow conditions and increase invasion. 
 
The main two proteins components of the basement membrane are laminin V 
and collagen type IV. We decided to further confirm loss of basement membrane due 
to IFF using another protein marker and stained the spheroids with collagen IV. In 
line with the loss of laminin V staining previously observed, we saw a loss of 
basement membrane associated collagen IV staining in the IFF samples (Fig. 28A). 
Analysis of these NeuN acini showed a greater than 50% decreased in basement 
membrane associated collagen IV staining under IFF (Fig. 28B) (p<0.05). 
Interestingly, MCF10A acini also displayed an IFF-induced decrease in collagen IV 
staining; however in this case, the difference was not statistically significant. Figure 
28B is the percentage ratio of collagen IV staining and total cell surface staining (as 
measured by F-actin staining).  
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Figure 28: Interstitial fluid flow induces loss of basement membrane associated collagen type IV. 
A) NeuN 12-day old acini plus 2 days under flow or static conditions; decreased collagen IV 
staining in flow conditions and increase in invasive protrusions (arrow). B) Image analysis using 
MATLAB of collagen IV fluorescent intensity differences. Data is represented as percentage 
Collagen IV (red) stain when compared to Phalloidin (green) from NeuN flow: 9; NeuN static: 
16; MCF10A flow: 16; MCF10A static: 16. All values are mean ± SEM. *: p < 0.05. 
 
Interstitial fluid flow increases spheroids protrusions 
Basement membrane degradation is a hallmark for initiation of 3D invasion 
along with increase spheroid protrusions. To quantify spheroids protrusions, we 
counted the number of outward cell protrusions per acini (as shown by the arrows in 
Fig. 29A). We manually counted the number of protrusion in each acinus and 
observed that IFF increased the number of cellular protrusions from MCF10A and 
NeuN spheroids (Fig. 29B-C). We defined spheroid protrusions as extensions 
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outward of the main structure and quantified them using two separate approaches. 
First we classified spheroids displaying at least one protrusion as invasive spheroids 
and compared that number to the total number of spheroids to obtain a percentage 
invasive spheroids value (Fig 29B). This allowed us to observe that IFF increased the 
number of MCF10A invasive spheroids from 0 to 17%. IFF increased the number of 
NeuN invasive spheroids from 20% to 71%. The vast majority of NeuT spheroids 
(89%) were already invasive regardless of IFF. Secondly, we manually counted the 
number of protrusion in each spheroid to identify the role of IFF in increasing the 
total number of protrusions per spheroids. Here we observed that although both 
MCF10A and NeuN flow samples had higher averages of protrusions, these were not 
statistically significant when compared to static spheroids (Fig. 29C). 
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Figure 29: Interstitial fluid flow increases number protrusions of non-invasive breast cancer 
spheroids. A) Representative image of acini without protrusions (MCF10A) and acini with more 
than 6 protrusions (NeuT). Arrows points to protrusions. B) Percentage of acini with at least 1 
protrusion. Protrusions were identified as extension from main structures. C) Average number 
of protrusions per spheroids. MCF10A static: 15; MCF10A flow: 25; NeuN static: 7; NeuN flow: 
7; NeuT static: 10; NeuT flow: 8 in both A and B. 
 
Interstitial fluid flow leads to PI3K phosphorylation of 3D spheroids 
We previously observed that IFF increases invasion of single cells through 
PI3K phosphorylation (see Chapter 4). This led us to question the role of PI3K in 
IFF-dependent invasion of spheroids. In order to measure the level of this kinase in 
our samples, we isolated spheroids from gels after the 3-D invasion assay and 
harvested proteins. Western blot revealed an increase of phosphorylated p85 (the 
regulatory subunit of class I PI3K complex) in response to IFF in MCF10A and NeuN 
but not in NeuTs (Fig. 30). 
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Figure 30: Interstitial fluid flow induces phosphorylation of PI3K in spheroids. Representative 
western blot of phosphorylation of PI3K regulatory subunit (p85) after 48 hours of static or flow 
conditions in 3-D acini structures embedded in a collagen matrix; A) β actin was used as loading 
control B) Total PI3K was used as loading control. 
 
5.4 Discussion 
Numerous studies have identified key components of the tumor 
microenvironments that alter tumor progression [30, 32, 34-36, 38-40, 60, 159, 162, 
163]. Aside from the tumor and epithelial cells themselves, the tumor 
microenvironment includes all other components of the mammary gland (stroma-
associated cells, matrix proteins, soluble factors and biophysical forces) and these 
have each been implicated in the suppression or promotion of tumor initiation, growth 
and development. Here we present the role of yet another microenvironment factor in 
the initial stages of cancer invasion and metastasis.  
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While we were aware of the ability of IFF to increase invasion of individual 
single cells, we aimed to investigate its effects on complex 3D multicellular acini that 
mimic tumor in vivo structures. The role IFF plays on 3D multicellular structures had 
never been studied. Hence, we showed for the first time that IFF modulated invasion 
of acini through increase in protrusion-positive spheroids, number of protrusions per 
spheroids, basement membrane associated protein degradation, and PI3K 
phosphorylation.  
Early signs of tumor invasion and metastasis include basement membrane 
degradation, cellular protrusions and changes in cell and extracellular matrix 
interaction [8, 20]. The degradation or decreased expression of basement membrane 
associated proteins such as laminin V and collagen IV is a necessary step in vivo to 
allow for cell migration out of the mammary ducts into the surrounding stroma [113], 
and onwards into lymphatic and/or blood vessels. Because recreating the architecture 
of in vivo structures allow for more relevant physiological models in the study of 
cancer [164], we firstly developed a 3-D cell culture model that mimics interstitial 
fluid flow dynamics in normal, DCIS-like and IDC-like tumors. Secondly, we used 
this model to visualize the effects of IFF on the early steps of invasion which include 
basement membrane degradation and cellular protrusions. 
In in vitro studies, cellular protrusions have been used as a positive marker for 
invasion [165-167] in addition to basement membrane degradation.  The type of 
extensions and mode of cellular invasion away from the main tumor can be used to 
develop better cancer therapies. Cancer cells usually adopt distinct migration and 
invasion patterns. These are categorized as mesenchymal, amoeboid or collective cell 
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migration [49]. Each of these invasion patterns rely on a set of signaling cascades and 
these can be used as molecular targets in therapy development for advance disease in 
patients. 
Most studies on IFF have been based on single cell migration and invasion 
within a matrix [76, 78, 86].  This approach is effective at identifying molecular 
signaling pathways activated by IFF and their consequences on cellular motility. 
However, their relevance to in vivo systems can only be inferred. Single cell 
migration out of a compact multicellular structure of cells requires loss of cell-to-cell 
contact that is tightly regulated by e-cadherins and integrins, and this phenomenon is 
not displayed in individual cells embedded in a matrix.  Our newly developed 
approach allowed us to recapitulate pathological tissue architecture and allowed us to 
determine the effects of IFF on the invasion of these 3D structures.   
In cancer, IFF originates from both leakage of normal blood vessels (outside 
the tumor) and tumor core (inside the tumor) leakage. Our current model did not 
consider the elevated IFF that is the result of additional angiogenic blood vessels 
present within the tumor especially in late stage DCIS and IDC. Although the flow 
velocities used in this study were closer to normal tissue IFF velocities, it was 
intriguing to demonstrate that such low IFF velocities were significant enough to 
initiate spheroids invasion.  Future work will compare the effects of higher IFF 
velocities on both HER2 positive and negative acini. 
Using a 3-D breast cancer model, we demonstrate for the first time that IFF 
induces the invasion of HER2 positive DCIS-like spheroids through a PI3K-
dependent mechanism. We measured increased spheroid protrusions and loss of 
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basement membrane associated proteins (laminin V and collagen IV) in the presence 
on IFF. Further experiments are underway to elucidate the complete pathways 
activated by fluid flow in these structures. This study will allow us to identify 
therapeutic targets that may aid in DCIS management and treatment. 
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CHAPTER 6: Conclusions and future work 
6.1 Major Findings and Significance 
Introduction 
The current study provides a foundation for interstitial fluid flow (IFF) 
signaling in HER2 positive breast cancer cells. Given that the combined role of IFF 
and HER2 expression in breast cancer invasion and progression had not been 
previously studied, this work identified key signaling proteins necessary in this 
pathway. The main findings of this study are that (a) physiological levels of IFF 
induce invasion of both single breast cancer cells and 3D spheroids via activation of 
PI3K; (b) although HER2 is necessary for most invasion in HER2 positive cells, and 
changes induced by HER2 overexpression probably plays an indirect role in IFF 
response, IFF induces invasion through a pathway independent of direct HER2 
activity; (c) IFF mediated invasion requires CXCR4 signaling and a CXCL12 
gradient in HER2 positive cells that have undergone EMT; and (d) IFF induces 
protein expression in cells consistent with EMT and renders cells more resistant to 
HER2-targeting therapies. 
 
Previous IFF-induced mechanisms 
Prior to the work presented here, IFF had been hypothesized to increase 
invasion of cells via two separate mechanisms. In the first mechanism, increased IFF-
induced invasion is regulated by autocrine signaling in which IFF alters the levels of a 
specific invasion-inducing chemokine around the cells leading to migration in the 
direction of fluid flow. This mechanism is termed autologous chemotaxis and was 
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shown in three separate cellular systems and through two separate chemokines 
(CCR7 and CXCR4) [75, 76, 78]. Interestingly, all cells previously shown to invade 
through this mechanism are invasive and metastatic cells. We present evidence 
supporting CXCR4-dependent autologous chemotaxis in breast cancer cells. 
However, we demonstrate for the first time that this mechanism is specific to invasive 
cells like those that have undergone EMT, and non-invasive cells do not respond to 
IFF through chemokine signaling.   
CXCR4/CXCL12 axis was previously identified as necessary for this IFF-
induced autologous chemotaxis response in glioma cells [76]. Our results show that 
autocrine CXCL12 secretion and autologous CXCR4/CXCL12 chemotaxis is 
important only in IDC cells and not in pre-invasive cells. Because the levels of 
CXCR4 were not altered between our invasive and non-invasive cells, this suggests 
that during breast cancer progression, once the cells have acquired the invasive 
phenotype though EMT, they become more sensitive to chemokine gradients and 
develop a chemokine-dependent directional migration. The switch from chemokine 
dependent to chemokine-independent probably helps in facilitating metastasis and 
organ homing. It further emphasizes the importance of CXCR4 signaling in breast 
cancer invasion similar to what was observed in previous studies [143].   
The second mechanism of IFF-induced invasion that was previously 
demonstrated is shown to be a consequence of IFF-induced changes to cellular 
interactions with the ECM via MMPs and adhesion proteins (integrins, focal adhesion 
kinases (FAKs) and CD44) [77, 79, 86]. Our finding do not suggest the importance of 
MMPs in the IFF-induced invasion of our breast cancer cell model since inhibition of 
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MMP activity using the pan-MMP inhibitor GM6001 did not ablate IFF-induced 
invasion. Because changes to MMP expression and activity are hallmark of cancer 
progression and the fact that these enzymes are highly secreted by metastatic cells to 
facilitate migration though matrix degradation, we cannot exclude their potential 
importance in the IFF-induced pathway. What we observed may be specific to the 
components of the matrix used in our model (e.g. the presence of matrigel as opposed 
to collagen-only which was used in studies identifying the important role of MMP in 
IFF-induced invasion), and the invasive potential of the cells (e.g. MMPs may be 
necessary for NeuT migration and not NeuN). This same principle can be applied to 
the role of FAK in IFF-induced pathway because we found that inhibiting this kinase 
did not disrupt IFF-induced invasion. We did not however question the role of 
integrins and CD44 molecules in our system, and this can serve as the basis of future 
studies (see future studies section below). 
 
IFF and DCIS management 
The identified specific mechanisms of interstitial fluid flow in initiating 
invasion can serve as a basis for therapeutic development in the treatment of DCIS 
patients. To date, most patients diagnosed with DCIS are treated with harsh therapies 
including lumpectomy, mastectomy, radiation therapy to prevent invasive breast 
cancer (IDC) even though more than 50% of DCIS will never progress to IDC [168, 
169]. Our findings suggest that IFF velocities may serve as a potential marker for the 
classification of which DCIS patients are more at risk of developing IDC. This agrees 
with findings from a previous study showing a positive correlation between 
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interstitial fluid flow, pressure, and lymph node metastasis in several types of human 
cancers [67]. Additional studies still remain to be done nevertheless elevated levels of 
IFF may be correlated with higher rates of breast cancer invasion and metastasis 
especially in vivo. 
 
IFF and PI3K 
 The PI3K pathway is known as one of the most important pathways in cancer 
and is implicated in cell growth, invasion, proliferation and differentiation [152, 170, 
171]. For this reason, numerous cancer therapies targeting this pathway have been 
developed [172, 173]. PI3K is usually activated by receptor tyrosine kinases such as 
HER family members who bind the PI3K complex through either specific p85 
binding sites or recruit chaperone proteins [174]. In many cancers however, 
constitutive activation of this pathway has been observed [175, 176]. The current 
project identifies IFF as a potential indirect contributor to PI3K activation in cancers. 
It also supports the importance of targeting this pathway in order to curtail breast 
cancer invasion in both DCIS and IDC, especially in those with abnormally elevated 
IFF. We show that by specifically blocking either p110α or p110β, we can decrease 
IFF-induced invasion in IDC cells. This means that in IDC patients requiring a 
specific p110 isoform for normal function or response to other unrelated therapies 
(depression, diabetes [176, 177]), the second isoform may be targeted. Inhibiting both 
isoforms using pan-PI3K inhibitors like most used currently in the clinic for breast 
cancer invasion can inadvertently affect the patients quality of life or health. 
Therefore, targeted p110 isoforms therapy will be more beneficial [178]. 
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 Compared to EGFR in MCF10A and CXCR4 in NeuT, we did not identify the 
specific upstream mediator of IFF-induced invasion in NeuN. Integrins are known 
activators of PI3K and their expressions are altered during cancer progression as the 
cells loose expression of specific basement membrane associated integrins (α6β4) and 
gain expression of others such as α5β5 [179]. Because integrins are known cellular 
transducers of mechanical signals, and we show through microarray analysis that the 
expression of both integrin α6β4 and α6β6 is down-regulated in NeuT compared to 
NeuN, this suggests these two integrins as potential upstream activators of IFF-
induced PI3K in NeuN. Platelet-derived growth factors receptors (PDGFRs) are 
another potential IFF-induced PI3K activators in NeuN since these growth factors 
along with their receptors have been associated with shear stress induced invasion and 
PI3K activation [180-182].  
The fact that all three identified pathways converge at PI3K and p110α 
suggest that this kinase is important for cellular invasion throughout cancer 
progression however its specific activator changes as the tumor progresses and the 
cells transform from epithelial characteristics to mesenchymal and their functions 
change. 
 
IFF and HER2 
The knowledge gained from this study has the potential to impact HER2 
breast cancer management. A major hurdle in HER2 cancer therapy has been the de 
novo and acquired development of drug resistance observed in the clinic after months 
to years of therapy success [183]. Our findings demonstrate that HER2 positive cells 
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can still invade and proliferate in the presence of HER2 inhibitors when influenced by 
IFF. This reveals IFF as a contributor to HER2 drug resistance and tolerance. It also 
suggests that HER2 drug resistance may be prevented by developing new treatment 
approaches that modulate IFF levels in the tissue. In addition, combination therapies 
targeting both members of the here-presented IFF-activated molecular pathways 
(p110, CXCR4) along with current HER2 drug targets (Herceptin, Lapatinib) may be 
more effective at reducing the rates of invasion in HER2 positive breast cancer 
patients compared to HER2 therapies alone.  
EMT is sometimes followed by a loss of HER2 overexpression in HER2 
positive cells [121]. This may explain the spontaneous desensitization to HER2 
targeted therapies observed in some patients. The fact that our data demonstrates that 
IFF alters the expression of EMT markers further suggests its impact on HER2 
therapy resistance, cancer progression, and cancer cell differentiation.  
 
Single cells versus spheroids 
Most studies on IFF have been based on single cell migration and invasion 
[76, 78, 86]. Although this approach can effectively identify molecular signaling 
pathways activated by IFF and their consequences on cellular motility (see chapters 2, 
3, and 4), single cells display invasion dynamics that are not relevant to in pre-
invasive in vivo systems. Single cell migration out of a compact multicellular 
structure (mammary duct) requires alterations to both cell-to-cell and cell-to-ECM 
interactions that are not prominent in systems of individual cells embedded in a 
matrix. In addition, the basement membrane presents a physical barrier that cells need 
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to breakdown in order for invasion to occur. For this reason, results using our 
developed 3D spheroid model that recapitulate pathological tissue architecture are 
more relevant in studying the transition from DCIS to IDC. Using this approach, we 
demonstrate for the first time the impact of IFF on DCIS-like spheroids and this 
occurring also in a PI3K-dependent fashion. From these findings, we can postulate 
that IFF plays separate autonomous roles during cancer progression. First, it 
facilitates initiation of invasion out of the primary tumor site and second, it aid in 
directing single cell migration during metastasis. 
 
Conclusion 
In conclusion, this study provides evidence supporting the mechanism of 
autologous chemotaxis in IFF response, identifies additional IFF-induced 
mechanisms that are chemokine independent, and further demonstrates a hitherto 
undefined role of IFF on cell fate during breast cancer progression. In addition, our 
findings helped isolate the role each mechanical (IFF) and molecular factors (HER2) 
studied plays in initiating invasion, and has helped change the paradigm of how 
mechanical forces can interact with molecular factors to control tumor progression. 
 
6.2 Future Work 
The findings described here can be used to investigate several research topics. 
Our initial findings identified PI3K as a major component of all three IFF molecular 
pathways in all cell lines tested. Future work will focus on identifying both the 
upstream and downstream activators of PI3K that can modulate IFF-induced invasion 
  
93 
 
in HER2 positive non-invasive cancer cells and other HER2 negative DCIS-like cells. 
Our current hypothesis is that these may be integrins and/or PDGR as both are known 
inducers of PI3K and mechano-transducers. Targeting these receptors to questions 
their importance in IFF-induced signaling will require the use of pharmacological 
inhibitors, neutralizing antibodies or silencing RNAs. Further experiments to identify 
the complete pathway activated by IFF in each of these cells will also be beneficial.  
Since IFF-induced invasion in DCIS cells occurred specifically through 
p110α, future breast cancer therapy development could focus on targeting this 
isoform in HER2 positive DCIS in order to decrease their risks of transitioning to 
IDC. This in turn may aid in decreasing the overall number of deaths associated with 
breast cancer.   
One limitation of our study was the difference in pressure gradients between 
our model and most in vivo systems. The hydrostatic pressure difference generated by 
our 3D system was approximately 1 mm Hg; however levels in vivo are much larger 
despite the less permeable environment. This suggests that higher pressure gradients 
in vivo are required to generate a similar amount of IFF, and this may impact how 
cells respond in vivo compared to in vitro [67, 184]. Future studies should therefore 
question the role of members of the identified IFF molecular pathway such as PI3K 
and CXCR4 in a model system that includes IFF velocities and pressures closer to 
those levels observed in vivo. The pressure and velocity levels can be increased by 
incorporating a manual pump in the system. The pump can therefore be set to several 
physiological levels higher than what was used in this model and pathological levels 
(high and low measured levels in tumors). Changes to invasion and response to 
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pharmacological inhibitors targeting CXCR4 and PI3K can then be compared 
between these conditions. 
In addition, animal studies will help bridge the gap of knowledge that 
currently exists between the mechanisms of IFF in the lab and in patients. Building 
upon the findings of the present study, we may be able to identify the role of normal 
and elevated levels of IFF in more complex but relevant systems (mice, human). 
Using MRI imaging for example to measure IFF velocities in the mammary fat pad of 
mice at multiple stages of breast cancer, IFF velocities could then be compared to the 
rates of invasion and number of metastasis, sites of metastasis and rate of survival. 
Identifying a correlation between flow velocities and invasion/metastasis in mouse 
models will aid in translating the findings of the current research to impacting human 
breast cancer. Through an improved understanding of IFF induced cell invasion, this 
research will have significant impact in helping determine how and why breast cancer 
cells invade, and what regulates the transition from DCIS to IDC.   
Interstitial fluid flow is just one of the many biophysical stimuli in vivo that 
alter cellular invasion. It remains however still largely ignored in cancer research and 
therapy development. Understanding the consequences of interstitial fluid flow and 
other biomechanical forces in the tumor microenvironment on cellular behavior will 
revolutionize our understanding of the importance of these biophysical forces in 
driving breast cancer progression. This will not only lead to better clinical 
management of breast cancer patients in particular but other cancer patients in general 
and indirectly decrease the mortality rates of cancer. 
  
95 
 
 
  
96 
 
LIST OF REFERENCES 
[1] A. C. Society, "Cancer Facts and Figures 2014," 2014. 
[2] A. Jemal, R. Siegel, J. Xu, and E. Ward, "Cancer statistics, 2010," CA Cancer 
J Clin, vol. 60, pp. 277-300, Sep-Oct 2010. 
[3] R. Siegel, D. Naishadham, and A. Jemal, "Cancer statistics, 2012," CA Cancer 
J Clin, vol. 62, pp. 10-29, Jan-Feb 2012. 
[4] N. A. Howlader N, Krapcho M, Neyman N, Aminou  R, Waldron W, 
Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, 
Lewis DR, Chen HS, Feuer EJ, Cronin KA, Edwards BK, "SEER Cancer Statistics 
Review, 1975-2008, National Cancer Institute. Bethesda, MD 
" http://seer.cancer.gov/csr/1975_2008/, vol. Based on the 2010 SEER data 
submission, Poster to the SEER web site, 2011. 
[5] J. L. Bos, "ras oncogenes in human cancer: a review," Cancer Res, vol. 49, pp. 
4682-9, Sep 1 1989. 
[6] D. J. Jerry, K. A. Dunphy, and M. J. Hagen, "Estrogens, regulation of p53 and 
breast cancer risk: a balancing act," Cell Mol Life Sci, vol. 67, pp. 1017-23, Apr 2010. 
[7] B. W. Morrison and P. Leder, "neu and ras initiate murine mammary tumors 
that share genetic markers generally absent in c-myc and int-2-initiated tumors," 
Oncogene, vol. 9, pp. 3417-26, Dec 1994. 
[8] D. Hanahan and R. A. Weinberg, "Hallmarks of cancer: the next generation," 
Cell, vol. 144, pp. 646-74, Mar 4 2011. 
[9] X. J. Ma, R. Salunga, J. T. Tuggle, J. Gaudet, E. Enright, P. McQuary, T. 
Payette, M. Pistone, K. Stecker, B. M. Zhang, Y. X. Zhou, H. Varnholt, B. Smith, M. 
Gadd, E. Chatfield, J. Kessler, T. M. Baer, M. G. Erlander, and D. C. Sgroi, "Gene 
expression profiles of human breast cancer progression," Proc Natl Acad Sci U S A, 
vol. 100, pp. 5974-9, May 13 2003. 
  
97 
 
[10] M. A. Cichon, A. C. Degnim, D. W. Visscher, and D. C. Radisky, 
"Microenvironmental influences that drive progression from benign breast disease to 
invasive breast cancer," J Mammary Gland Biol Neoplasia, vol. 15, pp. 389-97, Dec 
2010. 
[11] Z. P. Pavelic, L. Pavelic, E. E. Lower, M. Gapany, S. Gapany, E. A. Barker, 
and H. D. Preisler, "c-myc, c-erbB-2, and Ki-67 expression in normal breast tissue 
and in invasive and noninvasive breast carcinoma," Cancer Res, vol. 52, pp. 2597-
602, May 1 1992. 
[12] A. Ringberg, I. Andersson, K. Aspegren, and F. Linell, "Breast carcinoma in 
situ in 167 women--incidence, mode of presentation, therapy and follow-up," Eur J 
Surg Oncol, vol. 17, pp. 466-76, Oct 1991. 
[13] H. Kennecke, R. Yerushalmi, R. Woods, M. C. Cheang, D. Voduc, C. H. 
Speers, T. O. Nielsen, and K. Gelmon, "Metastatic behavior of breast cancer 
subtypes," J Clin Oncol, vol. 28, pp. 3271-7, Jul 10 2010. 
[14] D. C. Allred, S. K. Mohsin, and S. A. Fuqua, "Histological and biological 
evolution of human premalignant breast disease," Endocr Relat Cancer, vol. 8, pp. 
47-61, Mar 2001. 
[15] S. Damiani, M. Ludvikova, G. Tomasic, S. Bianchi, A. M. Gown, and V. 
Eusebi, "Myoepithelial cells and basal lamina in poorly differentiated in situ duct 
carcinoma of the breast. An immunocytochemical study," Virchows Arch, vol. 434, 
pp. 227-34, Mar 1999. 
[16] A. J. Guidi, S. J. Schnitt, L. Fischer, K. Tognazzi, J. R. Harris, H. F. Dvorak, 
and L. F. Brown, "Vascular permeability factor (vascular endothelial growth factor) 
expression and angiogenesis in patients with ductal carcinoma in situ of the breast," 
Cancer, vol. 80, pp. 1945-53, Nov 15 1997. 
[17] A. J. Guidi, L. Fischer, J. R. Harris, and S. J. Schnitt, "Microvessel density 
and distribution in ductal carcinoma in situ of the breast," J Natl Cancer Inst, vol. 86, 
pp. 614-9, Apr 20 1994. 
[18] H. J. Burstein, K. Polyak, J. S. Wong, S. C. Lester, and C. M. Kaelin, "Ductal 
carcinoma in situ of the breast," N Engl J Med, vol. 350, pp. 1430-41, Apr 1 2004. 
  
98 
 
[19] N. P. Castro, C. A. Osorio, C. Torres, E. P. Bastos, M. Mourao-Neto, F. A. 
Soares, H. P. Brentani, and D. M. Carraro, "Evidence that molecular changes in cells 
occur before morphological alterations during the progression of breast ductal 
carcinoma," Breast Cancer Res, vol. 10, p. R87, 2008. 
[20] M. Gormley, A. Tchafa, R. Meng, Z. Zhong, and A. A. Quong, "Proteomic 
profiling of infiltrating ductal carcinoma reveals increased cellular interactions with 
tissue microenvironment," J Proteome Res, vol. 11, pp. 2236-46, Apr 6 2012. 
[21] J. Boyages, G. Delaney, and R. Taylor, "Predictors of local recurrence after 
treatment of ductal carcinoma in situ: a meta-analysis," Cancer, vol. 85, pp. 616-28, 
Feb 1 1999. 
[22] B. Cutuli, J. Bernier, and P. Poortmans, "Radiotherapy in DCIS, an 
underestimated benefit?," Radiother Oncol, Jul 5 2014. 
[23] M. Badruddoja, "Ductal carcinoma in situ of the breast: a surgical 
perspective," Int J Surg Oncol, vol. 2012, p. 761364, 2012. 
[24] R. E. Roses, E. C. Paulson, A. Sharma, J. E. Schueller, H. Nisenbaum, S. 
Weinstein, K. R. Fox, P. J. Zhang, and B. J. Czerniecki, "HER-2/neu overexpression 
as a predictor for the transition from in situ to invasive breast cancer," Cancer 
Epidemiol Biomarkers Prev, vol. 18, pp. 1386-9, May 2009. 
[25] C. Ma, H. Lin, S. S. Leonard, X. Shi, J. Ye, and J. Luo, "Overexpression of 
ErbB2 enhances ethanol-stimulated intracellular signaling and invasion of human 
mammary epithelial and breast cancer cells in vitro," Oncogene, vol. 22, pp. 5281-90, 
Aug 14 2003. 
[26] I. Y. Kim, H. Y. Yong, K. W. Kang, and A. Moon, "Overexpression of ErbB2 
induces invasion of MCF10A human breast epithelial cells via MMP-9," Cancer Lett, 
vol. 275, pp. 227-33, Mar 18 2009. 
[27] C. J. Marshall, "Specificity of receptor tyrosine kinase signaling: transient 
versus sustained extracellular signal-regulated kinase activation," Cell, vol. 80, pp. 
179-85, Jan 27 1995. 
[28] F. Kimura, K. Iwaya, T. Kawaguchi, H. Kaise, K. Yamada, K. Mukai, O. 
Matsubara, N. Ikeda, and N. Kohno, "Epidermal growth factor-dependent 
  
99 
 
enhancement of invasiveness of squamous cell carcinoma of the breast," Cancer Sci, 
vol. 101, pp. 1133-40, May 2010. 
[29] S. T. Chen, T. L. Pan, H. F. Juan, T. Y. Chen, Y. S. Lin, and C. M. Huang, 
"Breast tumor microenvironment: proteomics highlights the treatments targeting 
secretome," J Proteome Res, vol. 7, pp. 1379-87, Apr 2008. 
[30] C. J. Olsen, J. Moreira, E. M. Lukanidin, and N. S. Ambartsumian, "Human 
mammary fibroblasts stimulate invasion of breast cancer cells in a three-dimensional 
culture and increase stroma development in mouse xenografts," BMC Cancer, vol. 10, 
p. 444, 2010. 
[31] I. Mercier, M. C. Casimiro, C. Wang, A. L. Rosenberg, J. Quong, A. Minkeu, 
K. G. Allen, C. Danilo, F. Sotgia, G. Bonuccelli, J. F. Jasmin, H. Xu, E. Bosco, B. 
Aronow, A. Witkiewicz, R. G. Pestell, E. S. Knudsen, and M. P. Lisanti, "Human 
breast cancer-associated fibroblasts (CAFs) show caveolin-1 downregulation and RB 
tumor suppressor functional inactivation: Implications for the response to hormonal 
therapy," Cancer Biol Ther, vol. 7, pp. 1212-25, Aug 2008. 
[32] D. A. Proia and C. Kuperwasser, "Stroma: tumor agonist or antagonist," Cell 
Cycle, vol. 4, pp. 1022-5, Aug 2005. 
[33] C. Kuperwasser, "The tumor stromal microenvironment as modulator of 
malignant behavior," J Mammary Gland Biol Neoplasia, vol. 15, pp. 377-9, Dec 
2010. 
[34] C. E. Lewis and R. Hughes, "Inflammation and breast cancer. 
Microenvironmental factors regulating macrophage function in breast tumours: 
hypoxia and angiopoietin-2," Breast Cancer Res, vol. 9, p. 209, 2007. 
[35] C. E. Lewis and J. W. Pollard, "Distinct role of macrophages in different 
tumor microenvironments," Cancer Res, vol. 66, pp. 605-12, Jan 15 2006. 
[36] M. P. Shekhar, J. Werdell, S. J. Santner, R. J. Pauley, and L. Tait, "Breast 
stroma plays a dominant regulatory role in breast epithelial growth and 
differentiation: implications for tumor development and progression," Cancer Res, 
vol. 61, pp. 1320-6, Feb 15 2001. 
  
100 
 
[37] A. F. Olumi, G. D. Grossfeld, S. W. Hayward, P. R. Carroll, T. D. Tlsty, and 
G. R. Cunha, "Carcinoma-associated fibroblasts direct tumor progression of initiated 
human prostatic epithelium," Cancer Res, vol. 59, pp. 5002-11, Oct 1 1999. 
[38] K. Pietras and A. Ostman, "Hallmarks of cancer: interactions with the tumor 
stroma," Exp Cell Res, vol. 316, pp. 1324-31, May 1 2010. 
[39] F. Xing, J. Saidou, and K. Watabe, "Cancer associated fibroblasts (CAFs) in 
tumor microenvironment," Front Biosci, vol. 15, pp. 166-79, 2010. 
[40] A. Noel, H. Emonard, M. Polette, P. Birembaut, and J. M. Foidart, "Role of 
matrix, fibroblasts and type IV collagenases in tumor progression and invasion," 
Pathol Res Pract, vol. 190, pp. 934-41, Oct 1994. 
[41] C. P. Ng, B. Hinz, and M. A. Swartz, "Interstitial fluid flow induces 
myofibroblast differentiation and collagen alignment in vitro," J Cell Sci, vol. 118, 
pp. 4731-9, Oct 15 2005. 
[42] J. M. Fleming, T. C. Miller, M. Quinones, Z. Xiao, X. Xu, M. J. Meyer, E. 
Ginsburg, T. D. Veenstra, and B. K. Vonderhaar, "The normal breast 
microenvironment of premenopausal women differentially influences the behavior of 
breast cancer cells in vitro and in vivo," BMC Med, vol. 8, p. 27, 2010. 
[43] I. Schmale, S. Liu, J. Rayhanabad, C. A. Russell, and S. F. Sener, "Ductal 
carcinoma in situ (DCIS) of the breast: Perspectives on biology and controversies in 
current management," J Surg Oncol, Jul 12 2011. 
[44] J. P. Thiery, H. Acloque, R. Y. Huang, and M. A. Nieto, "Epithelial-
mesenchymal transitions in development and disease," Cell, vol. 139, pp. 871-90, 
Nov 25 2009. 
[45] E. D. Hay, "The mesenchymal cell, its role in the embryo, and the remarkable 
signaling mechanisms that create it," Dev Dyn, vol. 233, pp. 706-20, Jul 2005. 
[46] J. P. Thiery and J. P. Sleeman, "Complex networks orchestrate epithelial-
mesenchymal transitions," Nat Rev Mol Cell Biol, vol. 7, pp. 131-42, Feb 2006. 
[47] J. P. Sleeman and J. P. Thiery, "SnapShot: The epithelial-mesenchymal 
transition," Cell, vol. 145, p. 162 e1, Apr 1 2011. 
  
101 
 
[48] S. Lamouille, J. Xu, and R. Derynck, "Molecular mechanisms of epithelial-
mesenchymal transition," Nat Rev Mol Cell Biol, vol. 15, pp. 178-96, Mar 2014. 
[49] M. Yilmaz and G. Christofori, "EMT, the cytoskeleton, and cancer cell 
invasion," Cancer Metastasis Rev, vol. 28, pp. 15-33, Jun 2009. 
[50] Y. Katsuno, S. Lamouille, and R. Derynck, "TGF-beta signaling and 
epithelial-mesenchymal transition in cancer progression," Curr Opin Oncol, vol. 25, 
pp. 76-84, Jan 2013. 
[51] N. A. Said and E. D. Williams, "Growth factors in induction of epithelial-
mesenchymal transition and metastasis," Cells Tissues Organs, vol. 193, pp. 85-97, 
2011. 
[52] J. A. Przybylo and D. C. Radisky, "Matrix metalloproteinase-induced 
epithelial-mesenchymal transition: tumor progression at Snail's pace," Int J Biochem 
Cell Biol, vol. 39, pp. 1082-8, 2007. 
[53] C. D. May, N. Sphyris, K. W. Evans, S. J. Werden, W. Guo, and S. A. Mani, 
"Epithelial-mesenchymal transition and cancer stem cells: a dangerously dynamic duo 
in breast cancer progression," Breast Cancer Res, vol. 13, p. 202, 2011. 
[54] S. A. Mani, W. Guo, M. J. Liao, E. N. Eaton, A. Ayyanan, A. Y. Zhou, M. 
Brooks, F. Reinhard, C. C. Zhang, M. Shipitsin, L. L. Campbell, K. Polyak, C. 
Brisken, J. Yang, and R. A. Weinberg, "The epithelial-mesenchymal transition 
generates cells with properties of stem cells," Cell, vol. 133, pp. 704-15, May 16 
2008. 
[55] N. Krawczyk, F. Meier-Stiegen, M. Banys, H. Neubauer, E. Ruckhaeberle, 
and T. Fehm, "Expression of Stem Cell and Epithelial-Mesenchymal Transition 
Markers in Circulating Tumor Cells of Breast Cancer Patients," Biomed Res Int, vol. 
2014, p. 415721, 2014. 
[56] C. J. Creighton, X. Li, M. Landis, J. M. Dixon, V. M. Neumeister, A. Sjolund, 
D. L. Rimm, H. Wong, A. Rodriguez, J. I. Herschkowitz, C. Fan, X. Zhang, X. He, A. 
Pavlick, M. C. Gutierrez, L. Renshaw, A. A. Larionov, D. Faratian, S. G. Hilsenbeck, 
C. M. Perou, M. T. Lewis, J. M. Rosen, and J. C. Chang, "Residual breast cancers 
after conventional therapy display mesenchymal as well as tumor-initiating features," 
Proc Natl Acad Sci U S A, vol. 106, pp. 13820-5, Aug 18 2009. 
  
102 
 
[57] X. Li, M. T. Lewis, J. Huang, C. Gutierrez, C. K. Osborne, M. F. Wu, S. G. 
Hilsenbeck, A. Pavlick, X. Zhang, G. C. Chamness, H. Wong, J. Rosen, and J. C. 
Chang, "Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy," J 
Natl Cancer Inst, vol. 100, pp. 672-9, May 7 2008. 
[58] T. M. Phillips, W. H. McBride, and F. Pajonk, "The response of CD24(-
/low)/CD44+ breast cancer-initiating cells to radiation," J Natl Cancer Inst, vol. 98, 
pp. 1777-85, Dec 20 2006. 
[59] M. Zhang, R. L. Atkinson, and J. M. Rosen, "Selective targeting of radiation-
resistant tumor-initiating cells," Proc Natl Acad Sci U S A, vol. 107, pp. 3522-7, Feb 
23 2010. 
[60] H. F. Dvorak, V. M. Weaver, T. D. Tlsty, and G. Bergers, "Tumor 
microenvironment and progression," J Surg Oncol, vol. 103, pp. 468-74, May 1 2011. 
[61] K. R. Levental, H. Yu, L. Kass, J. N. Lakins, M. Egeblad, J. T. Erler, S. F. 
Fong, K. Csiszar, A. Giaccia, W. Weninger, M. Yamauchi, D. L. Gasser, and V. M. 
Weaver, "Matrix crosslinking forces tumor progression by enhancing integrin 
signaling," Cell, vol. 139, pp. 891-906, Nov 25 2009. 
[62] T. P. Butler, F. H. Grantham, and P. M. Gullino, "Bulk transfer of fluid in the 
interstitial compartment of mammary tumors," Cancer Res, vol. 35, pp. 3084-8, Nov 
1975. 
[63] P. P. Provenzano, D. R. Inman, K. W. Eliceiri, J. G. Knittel, L. Yan, C. T. 
Rueden, J. G. White, and P. J. Keely, "Collagen density promotes mammary tumor 
initiation and progression," BMC Med, vol. 6, p. 11, 2008. 
[64] D. Fukumura, D. G. Duda, L. L. Munn, and R. K. Jain, "Tumor 
microvasculature and microenvironment: novel insights through intravital imaging in 
pre-clinical models," Microcirculation, vol. 17, pp. 206-25, Apr 2010. 
[65] S. R. Chary and R. K. Jain, "Direct measurement of interstitial convection and 
diffusion of albumin in normal and neoplastic tissues by fluorescence 
photobleaching," Proc Natl Acad Sci U S A, vol. 86, pp. 5385-9, Jul 1989. 
[66] H. Dafni, L. Landsman, B. Schechter, F. Kohen, and M. Neeman, "MRI and 
fluorescence microscopy of the acute vascular response to VEGF165: vasodilation, 
  
103 
 
hyper-permeability and lymphatic uptake, followed by rapid inactivation of the 
growth factor," NMR Biomed, vol. 15, pp. 120-31, Apr 2002. 
[67] T. Hompland, C. Ellingsen, K. M. Ovrebo, and E. K. Rofstad, "Interstitial 
fluid pressure and associated lymph node metastasis revealed in tumors by dynamic 
contrast-enhanced MRI," Cancer Res, vol. 72, pp. 4899-908, Oct 1 2012. 
[68] T. Hompland, C. Ellingsen, and E. K. Rofstad, "Preclinical evaluation of Gd-
DTPA and gadomelitol as contrast agents in DCE-MRI of cervical carcinoma 
interstitial fluid pressure," BMC Cancer, vol. 12, p. 544, 2012. 
[69] E. L. Fong, M. Santoro, M. C. Farach-Carson, F. K. Kasper, and A. G. Mikos, 
"Tissue Engineering Perfusable Cancer Models," Curr Opin Chem Eng, vol. 3, pp. 
112-117, Feb 2014. 
[70] M. Wu, H. B. Frieboes, S. R. McDougall, M. A. Chaplain, V. Cristini, and J. 
Lowengrub, "The effect of interstitial pressure on tumor growth: coupling with the 
blood and lymphatic vascular systems," J Theor Biol, vol. 320, pp. 131-51, Mar 7 
2013. 
[71] M. Welter and H. Rieger, "Interstitial fluid flow and drug delivery in 
vascularized tumors: a computational model," PLoS One, vol. 8, p. e70395, 2013. 
[72] G. Baronzio, L. Schwartz, M. Kiselevsky, A. Guais, E. Sanders, G. Milanesi, 
M. Baronzio, and I. Freitas, "Tumor interstitial fluid as modulator of cancer 
inflammation, thrombosis, immunity and angiogenesis," Anticancer Res, vol. 32, pp. 
405-14, Feb 2012. 
[73] U. Haessler, J. C. Teo, D. Foretay, P. Renaud, and M. A. Swartz, "Migration 
dynamics of breast cancer cells in a tunable 3D interstitial flow chamber," Integr Biol 
(Camb), vol. 4, pp. 401-9, Apr 2012. 
[74] A. C. Shieh and M. A. Swartz, "Regulation of tumor invasion by interstitial 
fluid flow," Phys Biol, vol. 8, p. 015012, Feb 2011. 
[75] J. D. Shields, M. E. Fleury, C. Yong, A. A. Tomei, G. J. Randolph, and M. A. 
Swartz, "Autologous chemotaxis as a mechanism of tumor cell homing to lymphatics 
via interstitial flow and autocrine CCR7 signaling," Cancer Cell, vol. 11, pp. 526-38, 
Jun 2007. 
  
104 
 
[76] J. M. Munson, R. V. Bellamkonda, and M. A. Swartz, "Interstitial flow in a 
3D microenvironment increases glioma invasion by a CXCR4-dependent 
mechanism," Cancer Res, vol. 73, pp. 1536-46, Mar 1 2013. 
[77] W. J. Polacheck, A. E. German, A. Mammoto, D. E. Ingber, and R. D. Kamm, 
"Mechanotransduction of fluid stresses governs 3D cell migration," Proc Natl Acad 
Sci U S A, vol. 111, pp. 2447-52, Feb 18 2014. 
[78] W. J. Polacheck, J. L. Charest, and R. D. Kamm, "Interstitial flow influences 
direction of tumor cell migration through competing mechanisms," Proc Natl Acad 
Sci U S A, vol. 108, pp. 11115-20, Jul 5 2011. 
[79] H. Qazi, R. Palomino, Z. D. Shi, L. L. Munn, and J. M. Tarbell, "Cancer cell 
glycocalyx mediates mechanotransduction and flow-regulated invasion," Integr Biol 
(Camb), vol. 5, pp. 1334-43, Nov 21 2013. 
[80] H. Qazi, Z. D. Shi, and J. M. Tarbell, "Fluid shear stress regulates the invasive 
potential of glioma cells via modulation of migratory activity and matrix 
metalloproteinase expression," PLoS One, vol. 6, p. e20348, 2011. 
[81] C. L. Helm, A. Zisch, and M. A. Swartz, "Engineered blood and lymphatic 
capillaries in 3-D VEGF-fibrin-collagen matrices with interstitial flow," Biotechnol 
Bioeng, vol. 96, pp. 167-76, Jan 1 2007. 
[82] D. O. Miteva, J. M. Rutkowski, J. B. Dixon, W. Kilarski, J. D. Shields, and M. 
A. Swartz, "Transmural flow modulates cell and fluid transport functions of 
lymphatic endothelium," Circ Res, vol. 106, pp. 920-31, Mar 19 2010. 
[83] Z. D. Shi, X. Y. Ji, H. Qazi, and J. M. Tarbell, "Interstitial flow promotes 
vascular fibroblast, myofibroblast, and smooth muscle cell motility in 3-D collagen I 
via upregulation of MMP-1," Am J Physiol Heart Circ Physiol, vol. 297, pp. H1225-
34, Oct 2009. 
[84] C. A. Kunder, A. L. St John, G. Li, K. W. Leong, B. Berwin, H. F. Staats, and 
S. N. Abraham, "Mast cell-derived particles deliver peripheral signals to remote 
lymph nodes," J Exp Med, vol. 206, pp. 2455-67, Oct 26 2009. 
[85] J. A. Pedersen, S. Lichter, and M. A. Swartz, "Cells in 3D matrices under 
interstitial flow: effects of extracellular matrix alignment on cell shear stress and drag 
forces," J Biomech, vol. 43, pp. 900-5, Mar 22 2010. 
  
105 
 
[86] A. C. Shieh, H. A. Rozansky, B. Hinz, and M. A. Swartz, "Tumor cell 
invasion is promoted by interstitial flow-induced matrix priming by stromal 
fibroblasts," Cancer Res, vol. 71, pp. 790-800, Feb 1 2011. 
[87] M. E. Fleury, K. C. Boardman, and M. A. Swartz, "Autologous morphogen 
gradients by subtle interstitial flow and matrix interactions," Biophys J, vol. 91, pp. 
113-21, Jul 1 2006. 
[88] J. M. Tarbell and Z. D. Shi, "Effect of the glycocalyx layer on transmission of 
interstitial flow shear stress to embedded cells," Biomech Model Mechanobiol, vol. 
12, pp. 111-21, Jan 2013. 
[89] S. A. Eccles, "The role of c-erbB-2/HER2/neu in breast cancer progression 
and metastasis," J Mammary Gland Biol Neoplasia, vol. 6, pp. 393-406, Oct 2001. 
[90] R. Kumar and R. A. Wang, "Protein kinases in mammary gland development 
and cancer," Microsc Res Tech, vol. 59, pp. 49-57, Oct 1 2002. 
[91] A. C. Shieh, "Biomechanical forces shape the tumor microenvironment," Ann 
Biomed Eng, vol. 39, pp. 1379-89, May 2011. 
[92] M. Makale, "Cellular mechanobiology and cancer metastasis," Birth Defects 
Res C Embryo Today, vol. 81, pp. 329-43, Dec 2007. 
[93] E. Thomas and G. Berner, "Prognostic and predictive implications of HER2 
status for breast cancer patients," Eur J Oncol Nurs, vol. 4, pp. 10-7, Mar 2000. 
[94] D. J. Slamon, G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich, and W. L. 
McGuire, "Human breast cancer: correlation of relapse and survival with 
amplification of the HER-2/neu oncogene," Science, vol. 235, pp. 177-82, Jan 9 1987. 
[95] U. Krishnamurti and J. F. Silverman, "HER2 in Breast Cancer: A Review and 
Update," Adv Anat Pathol, vol. 21, pp. 100-7, Mar 2014. 
[96] M. J. Reginato and S. K. Muthuswamy, "Illuminating the center: mechanisms 
regulating lumen formation and maintenance in mammary morphogenesis," J 
Mammary Gland Biol Neoplasia, vol. 11, pp. 205-11, Oct 2006. 
  
106 
 
[97] S. K. Muthuswamy, D. Li, S. Lelievre, M. J. Bissell, and J. S. Brugge, 
"ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in 
epithelial acini," Nat Cell Biol, vol. 3, pp. 785-92, Sep 2001. 
[98] A. M. Tchafa, A. D. Shah, S. Wang, M. T. Duong, and A. C. Shieh, "Three-
dimensional Cell Culture Model for Measuring the Effects of Interstitial Fluid Flow 
on Tumor Cell Invasion," J Vis Exp, 2012. 
[99] Y. Tang, J. Mackey, R. Lai, S. Ghosh, C. Santos, K. Graham, S. Damaraju, M. 
Pasdar, and L. Li, "Quantitative proteomic analysis of HER2 normal and 
overexpressing MCF-7 breast cancer cells revealed proteomic changes accompanied 
with HER2 gene amplification," J Proteomics, vol. 91C, pp. 200-209, Jul 11 2013. 
[100] N. Aceto, S. Duss, G. Macdonald, D. S. Meyer, T. C. Roloff, N. E. Hynes, and 
M. Bentires-Alj, "Co-expression of HER2 and HER3 receptor tyrosine kinases 
enhances invasion of breast cells via stimulation of interleukin-8 autocrine secretion," 
Breast Cancer Res, vol. 14, p. R131, Oct 12 2012. 
[101] L. Zhan, B. Xiang, and S. K. Muthuswamy, "Controlled activation of 
ErbB1/ErbB2 heterodimers promote invasion of three-dimensional organized 
epithelia in an ErbB1-dependent manner: implications for progression of ErbB2-
overexpressing tumors," Cancer Res, vol. 66, pp. 5201-8, May 15 2006. 
[102] S. L. Moulder, F. M. Yakes, S. K. Muthuswamy, R. Bianco, J. F. Simpson, 
and C. L. Arteaga, "Epidermal growth factor receptor (HER1) tyrosine kinase 
inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer 
cells in vitro and in vivo," Cancer Res, vol. 61, pp. 8887-95, Dec 15 2001. 
[103] G. G. Gomez, J. Wykosky, C. Zanca, F. B. Furnari, and W. K. Cavenee, 
"Therapeutic resistance in cancer: microRNA regulation of EGFR signaling 
networks," Cancer Biol Med, vol. 10, pp. 192-205, Dec 2013. 
[104] B. Markman, F. Javier Ramos, J. Capdevila, and J. Tabernero, "EGFR and 
KRAS in colorectal cancer," Adv Clin Chem, vol. 51, pp. 71-119, 2010. 
[105] K. Khazaie, V. Schirrmacher, and R. B. Lichtner, "EGF receptor in neoplasia 
and metastasis," Cancer Metastasis Rev, vol. 12, pp. 255-74, Sep 1993. 
  
107 
 
[106] M. Zhang, X. Zhang, S. Zhao, Y. Wang, W. Di, G. Zhao, M. Yang, and Q. 
Zhang, "Prognostic value of survivin and EGFR protein expression in triple-negative 
breast cancer (TNBC) patients," Target Oncol, Nov 15 2013. 
[107] A. El Hamidieh, N. Grammatikakis, and E. Patsavoudi, "Cell surface Cdc37 
participates in extracellular HSP90 mediated cancer cell invasion," PLoS One, vol. 7, 
p. e42722, 2012. 
[108] T. Smirnova, Z. N. Zhou, R. J. Flinn, J. Wyckoff, P. J. Boimel, M. Pozzuto, S. 
J. Coniglio, J. M. Backer, A. R. Bresnick, J. S. Condeelis, N. E. Hynes, and J. E. 
Segall, "Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer 
cell motility and metastasis," Oncogene, vol. 31, pp. 706-15, Feb 9 2012. 
[109] P. Arora, B. D. Cuevas, A. Russo, G. L. Johnson, and J. Trejo, "Persistent 
transactivation of EGFR and ErbB2/HER2 by protease-activated receptor-1 promotes 
breast carcinoma cell invasion," Oncogene, vol. 27, pp. 4434-45, Jul 24 2008. 
[110] C. Foroni, M. Broggini, D. Generali, and G. Damia, "Epithelial-mesenchymal 
transition and breast cancer: role, molecular mechanisms and clinical impact," Cancer 
Treat Rev, vol. 38, pp. 689-97, Oct 2012. 
[111] E. Hohenester and P. D. Yurchenco, "Laminins in basement membrane 
assembly," Cell Adh Migr, vol. 7, pp. 56-63, Jan-Feb 2013. 
[112] M. Egeblad, M. G. Rasch, and V. M. Weaver, "Dynamic interplay between 
the collagen scaffold and tumor evolution," Curr Opin Cell Biol, vol. 22, pp. 697-706, 
Oct 2010. 
[113] K. J. Davies, "The Complex Interaction of Matrix Metalloproteinases in the 
Migration of Cancer Cells through Breast Tissue Stroma," Int J Breast Cancer, vol. 
2014, p. 839094, 2014. 
[114] K. Tryggvason, M. Hoyhtya, and C. Pyke, "Type IV collagenases in invasive 
tumors," Breast Cancer Res Treat, vol. 24, pp. 209-18, 1993. 
[115] R. Espinosa Neira and E. P. Salazar, "Native type IV collagen induces an 
epithelial to mesenchymal transition-like process in mammary epithelial cells 
MCF10A," Int J Biochem Cell Biol, vol. 44, pp. 2194-203, Dec 2012. 
  
108 
 
[116] P. Turkki, K. E. Makkonen, M. Huttunen, J. P. Laakkonen, S. Yla-Herttuala, 
K. J. Airenne, and V. Marjomaki, "Cell susceptibility to baculovirus transduction and 
echovirus infection is modified by protein kinase C phosphorylation and vimentin 
organization," J Virol, vol. 87, pp. 9822-35, Sep 2013. 
[117] E. Bertran, E. Crosas-Molist, P. Sancho, L. Caja, J. Lopez-Luque, E. Navarro, 
G. Egea, R. Lastra, T. Serrano, E. Ramos, and I. Fabregat, "Overactivation of the 
TGF-beta pathway confers a mesenchymal-like phenotype and CXCR4-dependent 
migratory properties to liver tumor cells," Hepatology, vol. 58, pp. 2032-44, Dec 
2013. 
[118] J. Yu, W. Zhang, F. Gao, Y. X. Liu, Z. Y. Chen, L. Y. Cheng, S. F. Xie, and 
S. S. Zheng, "FBW7 increases chemosensitivity in hepatocellular carcinoma cells 
through suppression of epithelial-mesenchymal transition," Hepatobiliary Pancreat 
Dis Int, vol. 13, pp. 184-91, Apr 2014. 
[119] Y. Wang and B. P. Zhou, "Epithelial-mesenchymal Transition---A Hallmark 
of Breast Cancer Metastasis," Cancer Hallm, vol. 1, pp. 38-49, Mar 2013. 
[120] P. Mallini, T. Lennard, J. Kirby, and A. Meeson, "Epithelial-to-mesenchymal 
transition: what is the impact on breast cancer stem cells and drug resistance," Cancer 
Treat Rev, vol. 40, pp. 341-8, Apr 2014. 
[121] D. Lesniak, S. Sabri, Y. Xu, K. Graham, P. Bhatnagar, M. Suresh, and B. 
Abdulkarim, "Spontaneous epithelial-mesenchymal transition and resistance to HER-
2-targeted therapies in HER-2-positive luminal breast cancer," PLoS One, vol. 8, p. 
e71987, 2013. 
[122] D. R. Pattabiraman and R. A. Weinberg, "Tackling the cancer stem cells - 
what challenges do they pose?," Nat Rev Drug Discov, vol. 13, pp. 497-512, Jul 1 
2014. 
[123] A. Kumar, J. Xu, S. Brady, H. Gao, D. Yu, J. Reuben, and K. Mehta, "Tissue 
transglutaminase promotes drug resistance and invasion by inducing mesenchymal 
transition in mammary epithelial cells," PLoS One, vol. 5, p. e13390, 2010. 
[124] M. J. Hendrix, E. A. Seftor, Y. W. Chu, K. T. Trevor, and R. E. Seftor, "Role 
of intermediate filaments in migration, invasion and metastasis," Cancer Metastasis 
Rev, vol. 15, pp. 507-25, Dec 1996. 
  
109 
 
[125] M. Mimeault and S. K. Batra, "Molecular biomarkers of cancer 
stem/progenitor cells associated with progression, metastases, and treatment 
resistance of aggressive cancers," Cancer Epidemiol Biomarkers Prev, vol. 23, pp. 
234-54, Feb 2014. 
[126] C. Oliveras-Ferraros, B. Corominas-Faja, S. Cufi, A. Vazquez-Martin, B. 
Martin-Castillo, J. M. Iglesias, E. Lopez-Bonet, A. G. Martin, and J. A. Menendez, 
"Epithelial-to-mesenchymal transition (EMT) confers primary resistance to 
trastuzumab (Herceptin)," Cell Cycle, vol. 11, pp. 4020-32, Nov 1 2012. 
[127] G. Xie, A. Ji, Q. Yuan, Z. Jin, Y. Yuan, C. Ren, Z. Guo, Q. Yao, K. Yang, X. 
Lin, and L. Chen, "Tumour-initiating capacity is independent of epithelial-
mesenchymal transition status in breast cancer cell lines," Br J Cancer, vol. 110, pp. 
2514-23, May 13 2014. 
[128] F. T. Martin, R. M. Dwyer, J. Kelly, S. Khan, J. M. Murphy, C. Curran, N. 
Miller, E. Hennessy, P. Dockery, F. P. Barry, T. O'Brien, and M. J. Kerin, "Potential 
role of mesenchymal stem cells (MSCs) in the breast tumour microenvironment: 
stimulation of epithelial to mesenchymal transition (EMT)," Breast Cancer Res Treat, 
vol. 124, pp. 317-26, Nov 2010. 
[129] J. G. Parvani, M. A. Taylor, and W. P. Schiemann, "Noncanonical TGF-beta 
signaling during mammary tumorigenesis," J Mammary Gland Biol Neoplasia, vol. 
16, pp. 127-46, Jun 2011. 
[130] Y. Nagata, K. H. Lan, X. Zhou, M. Tan, F. J. Esteva, A. A. Sahin, K. S. Klos, 
P. Li, B. P. Monia, N. T. Nguyen, G. N. Hortobagyi, M. C. Hung, and D. Yu, "PTEN 
activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts 
trastuzumab resistance in patients," Cancer Cell, vol. 6, pp. 117-27, Aug 2004. 
[131] J. Ferlay, H. R. Shin, F. Bray, D. Forman, C. Mathers, and D. M. Parkin, 
"Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008," Int J 
Cancer, vol. 127, pp. 2893-917, Dec 15 2010. 
[132] P. Lu, V. M. Weaver, and Z. Werb, "The extracellular matrix: a dynamic 
niche in cancer progression," J Cell Biol, vol. 196, pp. 395-406, Feb 20 2012. 
[133] M. J. Paszek, N. Zahir, K. R. Johnson, J. N. Lakins, G. I. Rozenberg, A. 
Gefen, C. A. Reinhart-King, S. S. Margulies, M. Dembo, D. Boettiger, D. A. 
Hammer, and V. M. Weaver, "Tensional homeostasis and the malignant phenotype," 
Cancer Cell, vol. 8, pp. 241-54, Sep 2005. 
  
110 
 
[134] A. B. Ariffin, P. F. Forde, S. Jahangeer, D. M. Soden, and J. Hinchion, 
"Releasing pressure in tumors: what do we know so far and where do we go from 
here? A review," Cancer Res, vol. 74, pp. 2655-62, May 15 2014. 
[135] K. K. Haenssen, S. A. Caldwell, K. S. Shahriari, S. R. Jackson, K. A. Whelan, 
A. J. Klein-Szanto, and M. J. Reginato, "ErbB2 requires integrin alpha5 for anoikis 
resistance via Src regulation of receptor activity in human mammary epithelial cells," 
J Cell Sci, vol. 123, pp. 1373-82, Apr 15 2010. 
[136] S. A. Caldwell, S. R. Jackson, K. S. Shahriari, T. P. Lynch, G. Sethi, S. 
Walker, K. Vosseller, and M. J. Reginato, "Nutrient sensor O-GlcNAc transferase 
regulates breast cancer tumorigenesis through targeting of the oncogenic transcription 
factor FoxM1," Oncogene, vol. 29, pp. 2831-42, May 13 2010. 
[137] B. Geering, P. R. Cutillas, G. Nock, S. I. Gharbi, and B. Vanhaesebroeck, 
"Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers," Proc Natl 
Acad Sci U S A, vol. 104, pp. 7809-14, May 8 2007. 
[138] P. K. Vogt, J. R. Hart, M. Gymnopoulos, H. Jiang, S. Kang, A. G. Bader, L. 
Zhao, and A. Denley, "Phosphatidylinositol 3-kinase: the oncoprotein," Curr Top 
Microbiol Immunol, vol. 347, pp. 79-104, 2010. 
[139] R. Fritsch, I. de Krijger, K. Fritsch, R. George, B. Reason, M. S. Kumar, M. 
Diefenbacher, G. Stamp, and J. Downward, "RAS and RHO families of GTPases 
directly regulate distinct phosphoinositide 3-kinase isoforms," Cell, vol. 153, pp. 
1050-63, May 23 2013. 
[140] H. A. Dbouk, O. Vadas, A. Shymanets, J. E. Burke, R. S. Salamon, B. D. 
Khalil, M. O. Barrett, G. L. Waldo, C. Surve, C. Hsueh, O. Perisic, C. Harteneck, P. 
R. Shepherd, T. K. Harden, A. V. Smrcka, R. Taussig, A. R. Bresnick, B. Nurnberg, 
R. L. Williams, and J. M. Backer, "G protein-coupled receptor-mediated activation of 
p110beta by Gbetagamma is required for cellular transformation and invasiveness," 
Sci Signal, vol. 5, p. ra89, Dec 4 2012. 
[141] S. Jia, T. M. Roberts, and J. J. Zhao, "Should individual PI3 kinase isoforms 
be targeted in cancer?," Curr Opin Cell Biol, vol. 21, pp. 199-208, Apr 2009. 
[142] T. Sobolik, Y. J. Su, S. Wells, G. D. Ayers, R. S. Cook, and A. Richmond, 
"CXCR4 drives the metastatic phenotype in breast cancer through induction of 
CXCR2 and activation of MEK and PI3K pathways," Mol Biol Cell, vol. 25, pp. 566-
82, Mar 2014. 
  
111 
 
[143] M. Cojoc, C. Peitzsch, F. Trautmann, L. Polishchuk, G. D. Telegeev, and A. 
Dubrovska, "Emerging targets in cancer management: role of the CXCL12/CXCR4 
axis," Onco Targets Ther, vol. 6, pp. 1347-1361, 2013. 
[144] M. Oppermann, "Chemokine receptor CCR5: insights into structure, function, 
and regulation," Cell Signal, vol. 16, pp. 1201-10, Nov 2004. 
[145] R. Atta ur, K. Harvey, and R. A. Siddiqui, "Interleukin-8: An autocrine 
inflammatory mediator," Curr Pharm Des, vol. 5, pp. 241-53, Apr 1999. 
[146] H. Xu and S. C. Heilshorn, "Microfluidic investigation of BDNF-enhanced 
neural stem cell chemotaxis in CXCL12 gradients," Small, vol. 9, pp. 585-95, Feb 25 
2013. 
[147] C. J. Groger, M. Grubinger, T. Waldhor, K. Vierlinger, and W. Mikulits, 
"Meta-analysis of gene expression signatures defining the epithelial to mesenchymal 
transition during cancer progression," PLoS One, vol. 7, p. e51136, 2012. 
[148] A. H. Sims, A. A. Larionov, D. J. Harrison, and E. Katz, "Use of microarray 
analysis to investigate EMT gene signatures," Methods Mol Biol, vol. 1046, pp. 85-
95, 2013. 
[149] K. Aigner, B. Dampier, L. Descovich, M. Mikula, A. Sultan, M. Schreiber, W. 
Mikulits, T. Brabletz, D. Strand, P. Obrist, W. Sommergruber, N. Schweifer, A. 
Wernitznig, H. Beug, R. Foisner, and A. Eger, "The transcription factor ZEB1 
(deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of 
epithelial polarity," Oncogene, vol. 26, pp. 6979-88, Oct 25 2007. 
[150] M. Romagnoli, K. Belguise, Z. Yu, X. Wang, E. Landesman-Bollag, D. C. 
Seldin, D. Chalbos, S. Barille-Nion, P. Jezequel, M. L. Seldin, and G. E. Sonenshein, 
"Epithelial-to-mesenchymal transition induced by TGF-beta1 is mediated by Blimp-
1-dependent repression of BMP-5," Cancer Res, vol. 72, pp. 6268-78, Dec 1 2012. 
[151] J. Baselga, "Targeting the phosphoinositide-3 (PI3) kinase pathway in breast 
cancer," Oncologist, vol. 16 Suppl 1, pp. 12-9, 2011. 
[152] L. Zhao and P. K. Vogt, "Class I PI3K in oncogenic cellular transformation," 
Oncogene, vol. 27, pp. 5486-96, Sep 18 2008. 
  
112 
 
[153] Z. Zhang, C. Ni, W. Chen, P. Wu, Z. Wang, J. Yin, J. Huang, and F. Qiu, 
"Expression of CXCR4 and breast cancer prognosis: a systematic review and meta-
analysis," BMC Cancer, vol. 14, p. 49, 2014. 
[154] M. Iannone, M. Ventre, G. Pagano, P. Giannoni, R. Quarto, and P. A. Netti, 
"Defining an optimal Stromal Derived Factor-1 presentation for effective recruitment 
of mesenchymal stem cells in 3D," Biotechnol Bioeng, Jun 2 2014. 
[155] E. T. Roussos, J. S. Condeelis, and A. Patsialou, "Chemotaxis in cancer," Nat 
Rev Cancer, vol. 11, pp. 573-87, Aug 2011. 
[156] B. Mosadegh, W. Saadi, S. J. Wang, and N. L. Jeon, "Epidermal growth factor 
promotes breast cancer cell chemotaxis in CXCL12 gradients," Biotechnol Bioeng, 
vol. 100, pp. 1205-13, Aug 15 2008. 
[157] M. Swamydas, K. Ricci, S. L. Rego, and D. Dreau, "Mesenchymal stem cell-
derived CCL-9 and CCL-5 promote mammary tumor cell invasion and the activation 
of matrix metalloproteinases," Cell Adh Migr, vol. 7, pp. 315-24, May-Jun 2013. 
[158] N. A. Howlader N, Krapcho M, Garshell J, Neyman N, Altekruse SF, Kosary 
CL, Yu M, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Lewis DR, Chen HS, Feuer EJ, 
Cronin KA (eds). (2013). SEER Cancer Statistics Review, 1975-2010.  
[159] M. Ham and A. Moon, "Inflammatory and microenvironmental factors 
involved in breast cancer progression," Arch Pharm Res, Nov 13 2013. 
[160] M. L. Gatza, H. N. Kung, K. L. Blackwell, M. W. Dewhirst, J. R. Marks, and 
J. T. Chi, "Analysis of tumor environmental response and oncogenic pathway 
activation identifies distinct basal and luminal features in HER2-related breast tumor 
subtypes," Breast Cancer Res, vol. 13, p. R62, 2011. 
[161] M. J. Reginato, K. R. Mills, E. B. Becker, D. K. Lynch, A. Bonni, S. K. 
Muthuswamy, and J. S. Brugge, "Bim regulation of lumen formation in cultured 
mammary epithelial acini is targeted by oncogenes," Mol Cell Biol, vol. 25, pp. 4591-
601, Jun 2005. 
[162] L. Ronnov-Jessen and M. J. Bissell, "Breast cancer by proxy: can the 
microenvironment be both the cause and consequence?," Trends Mol Med, vol. 15, 
pp. 5-13, Jan 2009. 
  
113 
 
[163] M. J. Bissell, V. M. Weaver, S. A. Lelievre, F. Wang, O. W. Petersen, and K. 
L. Schmeichel, "Tissue structure, nuclear organization, and gene expression in normal 
and malignant breast," Cancer Res, vol. 59, pp. 1757-1763s; discussion 1763s-1764s, 
Apr 1 1999. 
[164] P. A. Vidi, M. J. Bissell, and S. A. Lelievre, "Three-dimensional culture of 
human breast epithelial cells: the how and the why," Methods Mol Biol, vol. 945, pp. 
193-219, 2013. 
[165] K. M. Pettee, K. M. Dvorak, A. L. Nestor-Kalinoski, and K. M. Eisenmann, 
"An mDia2/ROCK Signaling Axis Regulates Invasive Egress from Epithelial Ovarian 
Cancer Spheroids," PLoS One, vol. 9, p. e90371, 2014. 
[166] Y. Meng, Z. Lu, S. Yu, Q. Zhang, Y. Ma, and J. Chen, "Ezrin promotes 
invasion and metastasis of pancreatic cancer cells," J Transl Med, vol. 8, p. 61, 2010. 
[167] K. S. Klos, J. K. Warmka, D. M. Drachenberg, L. Chang, G. W. Luxton, C. T. 
Leung, K. L. Schwertfeger, and E. V. Wattenberg, "Building Bridges toward 
Invasion: Tumor Promoter Treatment Induces a Novel Protein Kinase C-Dependent 
Phenotype in MCF10A Mammary Cell Acini," PLoS One, vol. 9, p. e90722, 2014. 
[168] H. G. Welch, S. Woloshin, and L. M. Schwartz, "The sea of uncertainty 
surrounding ductal carcinoma in situ--the price of screening mammography," J Natl 
Cancer Inst, vol. 100, pp. 228-9, Feb 20 2008. 
[169] A. S. Kumar, V. Bhatia, and I. C. Henderson, "Overdiagnosis and 
overtreatment of breast cancer: rates of ductal carcinoma in situ: a US perspective," 
Breast Cancer Res, vol. 7, pp. 271-5, 2005. 
[170] S. Brader and S. A. Eccles, "Phosphoinositide 3-kinase signalling pathways in 
tumor progression, invasion and angiogenesis," Tumori, vol. 90, pp. 2-8, Jan-Feb 
2004. 
[171] M. Osaki, M. Oshimura, and H. Ito, "PI3K-Akt pathway: its functions and 
alterations in human cancer," Apoptosis, vol. 9, pp. 667-76, Nov 2004. 
[172] K. D. Courtney, R. B. Corcoran, and J. A. Engelman, "The PI3K pathway as 
drug target in human cancer," J Clin Oncol, vol. 28, pp. 1075-83, Feb 20 2010. 
  
114 
 
[173] J. A. Fresno Vara, E. Casado, J. de Castro, P. Cejas, C. Belda-Iniesta, and M. 
Gonzalez-Baron, "PI3K/Akt signalling pathway and cancer," Cancer Treat Rev, vol. 
30, pp. 193-204, Apr 2004. 
[174] M. D. Marmor, K. B. Skaria, and Y. Yarden, "Signal transduction and 
oncogenesis by ErbB/HER receptors," Int J Radiat Oncol Biol Phys, vol. 58, pp. 903-
13, Mar 1 2004. 
[175] Y. W. Yi, H. J. Kang, H. J. Kim, J. S. Hwang, A. Wang, and I. Bae, 
"Inhibition of constitutively activated phosphoinositide 3-kinase/AKT pathway 
enhances antitumor activity of chemotherapeutic agents in breast cancer susceptibility 
gene 1-defective breast cancer cells," Mol Carcinog, vol. 52, pp. 667-75, Sep 2013. 
[176] R. M. Larive, G. Moriggi, M. Menacho-Marquez, M. Canamero, E. Alava, B. 
Alarcon, M. Dosil, and X. R. Bustelo, "Contribution of the R-Ras2 GTP-binding 
protein to primary breast tumorigenesis and late-stage metastatic disease," Nat 
Commun, vol. 5, p. 3881, 2014. 
[177] T. Asano, M. Fujishiro, A. Kushiyama, Y. Nakatsu, M. Yoneda, H. Kamata, 
and H. Sakoda, "Role of phosphatidylinositol 3-kinase activation on insulin action 
and its alteration in diabetic conditions," Biol Pharm Bull, vol. 30, pp. 1610-6, Sep 
2007. 
[178] D. A. Fruman and C. Rommel, "PI3K and cancer: lessons, challenges and 
opportunities," Nat Rev Drug Discov, vol. 13, pp. 140-56, Feb 2014. 
[179] A. Bianchi, M. E. Gervasi, and A. Bakin, "Role of beta5-integrin in epithelial-
mesenchymal transition in response to TGF-beta," Cell Cycle, vol. 9, pp. 1647-59, 
Apr 15 2010. 
[180] Y. X. Qi, J. Jiang, X. H. Jiang, X. D. Wang, S. Y. Ji, Y. Han, D. K. Long, B. 
R. Shen, Z. Q. Yan, S. Chien, and Z. L. Jiang, "PDGF-BB and TGF-{beta}1 on cross-
talk between endothelial and smooth muscle cells in vascular remodeling induced by 
low shear stress," Proc Natl Acad Sci U S A, vol. 108, pp. 1908-13, Feb 1 2011. 
[181] Q. L. Li, F. M. Gu, Z. Wang, J. H. Jiang, L. Q. Yao, C. J. Tan, X. Y. Huang, 
A. W. Ke, Z. Dai, J. Fan, and J. Zhou, "Activation of PI3K/AKT and MAPK pathway 
through a PDGFRbeta-dependent feedback loop is involved in rapamycin resistance 
in hepatocellular carcinoma," PLoS One, vol. 7, p. e33379, 2012. 
  
115 
 
[182] M. Jechlinger, A. Sommer, R. Moriggl, P. Seither, N. Kraut, P. Capodiecci, 
M. Donovan, C. Cordon-Cardo, H. Beug, and S. Grunert, "Autocrine PDGFR 
signaling promotes mammary cancer metastasis," J Clin Invest, vol. 116, pp. 1561-70, 
Jun 2006. 
[183] S. Ahmad, S. Gupta, R. Kumar, G. C. Varshney, and G. P. Raghava, 
"Herceptin resistance database for understanding mechanism of resistance in breast 
cancer patients," Sci Rep, vol. 4, p. 4483, 2014. 
[184] T. Yu, K. Liu, Y. Wu, J. Fan, J. Chen, C. Li, G. Zhu, Z. Wang, and L. Li, 
"High interstitial fluid pressure promotes tumor cell proliferation and invasion in oral 
squamous cell carcinoma," Int J Mol Med, vol. 32, pp. 1093-100, Nov 2013. 
 
  
  
116 
 
APPENDIX 
 
 
Figure 31: Schematic of the 3-D interstitial fluid flow invasion assay. First prepare gel solution 
using appropriate concentrations and volumes. Then add cells to gel solution and transfer to cell 
culture inserts. Finally add appropriate volume of media to each condition and incubate.  
Interstitial fluid flow is driven by a fluid pressure head. 
 
  
117 
 
 
Figure 32: Representative invaded cells after an experiment (mutated MCF10A mammary 
epithelial cell line). The cells on the membranes were fixed and stained with DAPI and Alexa 
Fluor 488-conjugated phalloidin to facilitate counting of invaded cells; A) Picture of the 
membrane under bright field; B) DAPI stained nuclei (in blue); C) Alexa Fluor 488-phalloidin 
stained F-actin (in green). Scale bar represents 50μm. 
 
Table 3: List of all inhibitors and neutralizing agents used in the projects along with their 
protein target 
  Inhibitor/Neutralizing agent Protein target 
1 Lapatinib Her2 
2 Triciribine Akt 
3 IMD0354 NFKB 
4 PD168393 HER ½ 
5 AG1478 HER 1  
6 SP60125 JNK II 
7 SB203580 p38 
8 LY294002 PI3K 
9 U0126 MEK 
10 PP2 SRC 
11 GM6001 MMP 
12 AMD3100 CXCR4 
13 WZ811 CXCR4 
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14 AS605240 P110 gamma 
15 CAL 101 P110 delta 
16 PIK75 P110 alpha 
17 TGX221 P110 beta 
18 PF573228 FAK 
19 BEZ235 MTOR 
20 Pertussis toxin GPCR 
21 SiRNA construct CXCL12 
22 Neutralizing antibody CXCL12 
23 Neutralizing antibody CXCR4 
24  Neutralizing antibody  CCR7 
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